
<TYPE>EX-10.11
<SEQUENCE>2
<FILENAME>d160523dex1011.htm
<DESCRIPTION>EX-10.11
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.11</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
  
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT 10.11 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Research Collaboration and License Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Agreement is entered into with effect as of the Effective Date (as defined below) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">by and between </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>F. Hoffmann-La Roche Ltd
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B>with an office and place of business at Grenzacherstrasse 124, 4070 Basel, Switzerland (&#147;<B>Roche Basel</B>&#148;)<B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Hoffmann-La Roche Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B>with an office and place of business at 150 Clove Road, Suite 8, Little Falls, New Jersey 07424, U.S.A. (&#147;<B>Roche US</B>&#148;; Roche Basel and
Roche US together referred to as &#147;<B>Roche</B>&#148;)<B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">on the one hand </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pieris Pharmaceuticals GmbH </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">with an office and place of business at Lise-Meitner-Str. 30, 83534 Freising, Germany <B>(&#147;Pieris Freising</B>&#148;) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pieris Pharmaceuticals, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">with an office and place of business at 255 State Street, 9<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Floor, Boston, MA 02109, USA
<B>(&#147;Pieris US</B>&#148;; Pieris Freising and Pieris US together referred to as &#147;<B>Pieris</B>&#148;) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">on the other hand. </P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the
exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and
Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of
the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Table of Contents </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

 
<TR> 
<TD WIDTH="2%"></TD> 
<TD VALIGN="bottom" WIDTH="1%"></TD> 
<TD WIDTH="3%"></TD> 
<TD VALIGN="bottom" WIDTH="1%"></TD> 
<TD WIDTH="91%"></TD> 
<TD VALIGN="bottom" WIDTH="1%"></TD> 
<TD></TD> 
<TD></TD> 
<TD></TD></TR>

 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top">1.&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top" COLSPAN="3">Definitions</TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.1</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Affiliate</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.2</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Agreement</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.3</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Agreement Term</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.4</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anticalin<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP></P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.5</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anticalin Affinity Maturation</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.6</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anticalin Expression</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.7</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anticalin Libraries</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.8</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anticalin Selection</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.9</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Applicable Law</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.10</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Binder</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.11</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Biosimilar Product</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.12</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Calendar Quarter</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.13</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Calendar Year</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.14</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change of Control</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.15</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change of Control Group</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.16</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Clinical Study</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.17</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Combination Product</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.18</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commercially Reasonable Efforts</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.19</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Companion Diagnostic</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.20</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Composition of Matter Claim</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.21</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compulsory Sublicense</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.22</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Confidential Information</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.23</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Continuation Election Notice</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.24</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Control</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.25</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cover</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.26</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effective Date</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.27</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entry into Portfolio</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.28</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">EU</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.29</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Event</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.30</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expert</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.31</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FDA</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.32</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FDCA</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.33</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Field</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.34</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Filing</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.35</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First Commercial Sale</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.36</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FTE</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.37</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FTE Rate</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.38</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Generated</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.39</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">GLP Tox Study</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.40</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Handle</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.41</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">HSR</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.42</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ICD</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.43</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IFRS</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.44</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Indication</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.45</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initiation</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.46</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Insolvency Event</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.47</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Invention</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR></TABLE> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 2 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

 
<TR> 
<TD WIDTH="2%"></TD> 
<TD VALIGN="bottom" WIDTH="1%"></TD> 
<TD WIDTH="3%"></TD> 
<TD VALIGN="bottom" WIDTH="1%"></TD> 
<TD WIDTH="91%"></TD> 
<TD VALIGN="bottom" WIDTH="1%"></TD> 
<TD></TD> 
<TD></TD> 
<TD></TD></TR>
 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.48</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">JP</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.49</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">JRC</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.50</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Know-How</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.51</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Modified Binder</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.52</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NDA</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.53</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net Sales</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.54</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Party</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.55</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patent Rights</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.56</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Phase I Study</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.57</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Phase II Study</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.58</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Phase III Study</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.59</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Phase-out Binder</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.60</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Phase-out Term</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.61</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pieris IP</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.62</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pieris Technology</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.63</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Product</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.64</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Regulatory Approval</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.65</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Regulatory Authority</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.66</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research Plan</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.67</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Roche Group</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.68</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Roche IP</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.69</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Roche Technology</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.70</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Royalty Term</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.71</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.72</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selected Binder</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.73</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sublicensee</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.74</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Target</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.75</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Territory</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.76</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third Party</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.77</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">US</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.78</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valid Claim</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">1.79</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional Definitions</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top">2.&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top" COLSPAN="3">Grant of License</TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">2.1</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research Licenses</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">2.2</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commercial License to Roche</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">2.3</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sublicense</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">2.4</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">License to Pieris [***]</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top">3.&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top" COLSPAN="3">Research Collaboration</TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top">4.</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top" COLSPAN="3">Diligence</TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">4.1</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">In General</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">4.2</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diligence of Roche [***]</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">4.3</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Limits</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top">5.</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top" COLSPAN="3">Development</TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">5.1</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Development by Roche</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">5.2</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision of Information</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top">6.</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top" COLSPAN="3">Governance</TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">6.1</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joint Research Committee</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">6.2</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Members</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">6.3</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Responsibilities of the JRC</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR></TABLE> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 3 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

 
<TR> 
<TD WIDTH="2%"></TD> 
<TD VALIGN="bottom" WIDTH="1%"></TD> 
<TD WIDTH="4%"></TD> 
<TD VALIGN="bottom" WIDTH="1%"></TD> 
<TD WIDTH="90%"></TD> 
<TD VALIGN="bottom" WIDTH="1%"></TD> 
<TD></TD> 
<TD></TD> 
<TD></TD></TR>
 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">6.4</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Meetings</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">6.5</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Minutes</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">6.6</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decisions</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">6.7</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Information Exchange</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">6.8</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alliance Director</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">6.9</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Limitations of Authority</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">6.10</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expenses</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">6.11</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lifetime</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top">7.&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top" COLSPAN="3">Supply</TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">7.1</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Clinical Supply of Product(s)</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">7.2</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commercial Supply of Product(s)</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top">8.</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top" COLSPAN="3">Regulatory</TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">8.1</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Responsibility</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top">9.</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top" COLSPAN="3">Commercialization</TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">9.1</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Responsibility</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">9.2</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Updates to Pieris</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top">10.</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top" COLSPAN="3">Payment</TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">10.1</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initiation Payment</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">10.2</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research Costs</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">10.3</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[***] Fee and [***] Fee</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">10.4</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Development Event Payments</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">10.5</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sales Based Events</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">10.6</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Royalty Payments</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">10.7</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Combination Product</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">10.8</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third Party Payments</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">10.9</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disclosure of Payments</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top">11.</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top" COLSPAN="3">Accounting and reporting</TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">11.1</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Timing of Payments</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">11.2</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Late Payment</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">11.3</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Method of Payment</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">11.4</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Currency Conversion</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">11.5</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reporting</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top">12.</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top" COLSPAN="3">Taxes</TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top">13.</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top" COLSPAN="3">Auditing</TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">13.1</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pieris&#146; Right to Audit</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">13.2</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit Reports</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">13.3</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Over- or Underpayment</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">13.4</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Duration of Audit Rights</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top">14.</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top" COLSPAN="3">Intellectual Property</TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">14.1</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ownership of Pieris IP and Roche IP</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">14.2</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ownership of Inventions</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">14.3</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">German Statute on Employee&#146;s Inventions</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">14.4</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prosecution of Patent Rights by Pieris</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">14.5</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prosecution of Patent Rights by Roche</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">14.6</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CREATE Act</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">14.7</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Defense</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">14.8</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Enforcement</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">14.9</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common Interest Disclosures</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">14.10</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;Biosimilar or interchangeable biological products</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR></TABLE> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 4 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

 
<TR> 
<TD WIDTH="2%"></TD> 
<TD VALIGN="bottom" WIDTH="1%"></TD> 
<TD WIDTH="4%"></TD> 
<TD VALIGN="bottom" WIDTH="1%"></TD> 
<TD WIDTH="90%"></TD> 
<TD VALIGN="bottom" WIDTH="1%"></TD> 
<TD></TD> 
<TD></TD> 
<TD></TD></TR>
 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">14.11</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patent Term Extensions</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top">15.</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top" COLSPAN="3">Representations and Warranties</TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">37</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">15.1</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third Party Patent Rights</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">37</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">15.2</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ownership of Patent Rights</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">37</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">15.3</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inventors</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">37</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">15.4</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grants</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">37</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">15.5</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Authorization</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">37</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">15.6</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Validity of Patent Rights</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">37</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">15.7</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ownership and Validity of Know-How</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">38</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">15.8</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No Claims</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">38</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">15.9</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No Conflict</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">38</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">15.10</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No Other Representations</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">38</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top">16.</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top" COLSPAN="3">Indemnification</TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">38</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top">17.</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top" COLSPAN="3">Liability</TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">17.1</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Limitation of Liability</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">17.2</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disclaimer</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top">18.</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top" COLSPAN="3">Obligation Not to Disclose Confidential Information</TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">18.1</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non-Use and Non-Disclosure</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">18.2</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Permitted Disclosure</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">18.3</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Press Releases</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">18.4</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Publications</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">18.5</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commercial Considerations</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top">19.</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top" COLSPAN="3">Term and Termination</TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">19.1</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commencement and Term</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">19.2</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Termination</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">19.3</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Consequences of Termination</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">19.4</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Survival</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top">20.</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top" COLSPAN="3">Bankruptcy</TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top">21.</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top" COLSPAN="3">Miscellaneous</TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">21.1</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Governing Law</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">21.2</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disputes</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">21.3</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assignment</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">21.4</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Debarment</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">21.5</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Independent Contractor</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">21.6</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unenforceable Provisions and Severability</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">21.7</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Waiver</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">21.8</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Appendices</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">21.9</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entire Understanding</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">21.10</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;Amendments</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">21.11</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;Invoices</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">49</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top">21.12</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;Notice</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;</TD> 
<TD NOWRAP VALIGN="bottom" ALIGN="right">49</TD> 
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 5 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Research Collaboration and License Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WHEREAS, Pieris has access to a proprietary Anticalin<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (lipocalin derived) discovery and
manufacturing platform and possesses proprietary technology and intellectual property rights relating thereto; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WHEREAS, Roche has access to the [***]
and [***] target protein and other tools and to [***] for [***] as well as expertise in the research, development, manufacture and commercialization of pharmaceutical and diagnostic products, in particular in the field of cancer immunotherapy; and
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WHEREAS, the Parties wish to combine their respective expertise to develop binders that [***]or [***] to [***] using Pieris Technology and Roche&#146;s
[***] for application in particular in cancer, and the Parties will collaborate from the beginning of lead identification through a mutually agreeable preclinical research stage set forth in the Research Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WHEREAS, Roche wishes to develop for commercialization such binders and explore their potential applications in various indications; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WHEREAS, Pieris is willing to grant to Roche rights to use certain of its intellectual property rights to make, use, offer for sale, sell and import and
export such binders (including Products containing such binders) in the Territory for use in the Field (as such terms are respectively defined below), as contemplated herein; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the mutual covenants and promises contained in this Agreement and other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the Parties hereto, intending to be legally bound, do hereby agree as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Definitions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As used in this Agreement, the following terms, whether used in the singular or plural, shall have the following meanings: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.1 Affiliate </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;Affiliate&#148; shall mean
any individual, corporation, association or other business entity that directly or indirectly controls, is controlled by, or is under common control with the Party in question. As used in this definition of &#147;Affiliate,&#148; the term
&#147;control&#148; shall mean the direct or indirect ownership of more than fifty percent (&gt;50%) of the stock having the right to vote for directors thereof or the ability to otherwise control the management of the corporation or other business
entity whether through the ownership of voting securities, by contract, resolution, regulation or otherwise. Anything to the contrary in this paragraph notwithstanding, Chugai Pharmaceutical Co., Ltd, a Japanese corporation
(&#147;<B>Chugai</B>&#148;) and Foundation Medicine, Inc., an American corporation (&#147;<B>Foundation</B>&#148;) and their subsidiaries, shall not be deemed an Affiliate of Roche unless Roche provides written notice to Pieris of its desire to
include Chugai and/or Foundation as an Affiliate of Roche. </P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 6 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.2 Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;Agreement&#148; shall mean this document including any and all appendices and amendments to it as may be added and/or amended from time to time
in accordance with the provisions of this Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.3 Agreement Term </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;Agreement Term&#148; shall mean the period of time commencing on the Effective Date and, unless this Agreement is terminated sooner as provided
in Article 19, expiring on the date when no royalty or other payment obligations under this Agreement are or will become due. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.4 Anticalin<SUP 
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;Anticalin<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&#148; shall
mean, whether in nucleic acid or protein form, (i)&nbsp;any lipocalin mutein isolated from the Anticalin Libraries, or (ii)&nbsp;any lipocalin mutein that, in each case, has been derived (either physically, intellectually or by reverse engineering,
in one (1)&nbsp;or more steps) from any lipocalin mutein referred to in Section (i)&nbsp;of this definition. For the sake of this Section, mutein shall mean a protein arising as a result of a mutation or a recombinant DNA procedure. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.5 Anticalin Affinity Maturation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term
&#147;Anticalin Affinity Maturation&#148; shall mean the process of engineering for an Anticalin to enhance its developability profile, such as increasing binding activities and specificity by introducing, e.g., one or more amino acid mutations.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.6 Anticalin Expression </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;Anticalin
Expression&#148; shall mean heterologous expression of an Anticalin in E. coli or other hosts as may be mutually agreed between the Parties. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.7
Anticalin Libraries </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;Anticalin Libraries&#148; shall mean any phage display library based on (i)&nbsp;the human [***] lipocalin (Uniprot
[***]), (ii)&nbsp;the human [***] lipocalin (Uniprot [***]), or (iii)&nbsp;[***], if applicable. For clarity, as of the Effective Date, Pieris [***] referred to in Section (iii)&nbsp;of this definition and this Section (iii)&nbsp;only becomes
relevant if and when Pieris [***] or [***] such [***] during the Agreement Term. For further clarity, notwithstanding anything to the contrary in this Agreement, Pieris has no obligation to [***] or [***] such [***] during the Term. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.8 Anticalin Selection </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;Anticalin
Selection&#148; shall mean the process of screening an Anticalin Library with a defined target through the process of phage display, within a solution, and physically separating the target, containing binding Anticalins, from the solution containing
non-binding Anticalins. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.9 Applicable Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term
&#147;Applicable Law&#148; shall mean any law, statute, ordinance, code, rule or regulation that has been enacted by a government authority (including without limitation, any Regulatory Authority and the United States Securities and Exchange
Commission (&#147;SEC&#148;)) and is in force as of the Effective Date or come into force during the Agreement Term, in each case to the extent that the same are applicable to the performance by the Parties of their respective obligations under this
Agreement. </P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 7 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.10 Binder </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;Binder&#148; shall mean an Anticalin<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> discovered under the Research Plan that [***] or
[***] the Target. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.11 Biosimilar Product </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term
&#147;Biosimilar Product&#148; shall mean a product that is not produced, licensed or owned by the Roche Group and is, according to the relevant Regulatory Authority for the given country or jurisdiction, highly similar with respect to a given
Product, notwithstanding minor differences in clinically inactive components, and with no clinically meaningful differences between the Biosimilar Product and the given Product in terms of the safety, purity and potency of the product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For countries or jurisdictions where no explicit biosimilar regulations exist, Biosimilar Product includes products which (i)&nbsp;have been deemed to be a
Biosimilar Product by a Regulatory Authority in another country or jurisdiction or (ii)&nbsp;have the identical amino acid sequence. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.12 Calendar
Quarter </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;Calendar Quarter&#148; shall mean each period of three (3)&nbsp;consecutive calendar months, ending March&nbsp;31,
June&nbsp;30, September&nbsp;30, and December&nbsp;31. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.13 Calendar Year </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;Calendar Year&#148; shall mean the period of time beginning on January&nbsp;1 and ending December&nbsp;31, except for the first year which shall
begin on the Effective Date and end on December&nbsp;31. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.14 Change of Control </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;Change of Control&#148; shall mean, with respect to a Party: (a)&nbsp;the acquisition by any Third Party of beneficial ownership of fifty
percent (50%)&nbsp;or more of the then outstanding common shares or voting power of such Party, other than acquisitions by employee benefit plans sponsored or maintained by such Party; (b)&nbsp;the consummation of a business combination involving
such Party, unless, following such business combination, the stockholders of such Party immediately prior to such business combination beneficially own directly or indirectly more than fifty percent (50%)&nbsp;of the then outstanding common shares
or voting power of the entity resulting from such business combination; or (c)&nbsp;the sale of all or substantially all of such Party&#146;s assets or business relating to the subject matter of the Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.15 Change of Control Group </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;Change of
Control Group&#148; shall mean with respect to a Party, the person or entity, or group of persons or entities, that is the acquirer of, or a successor to, a Party in connection with a Change of Control, together with affiliates of such persons or
entities that are not Affiliates of such Party immediately prior to the completion of such Change of Control of such Party. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.16 Clinical Study
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;Clinical Study&#148; shall mean a Phase I Study, Phase II Study, Phase III Study, as applicable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.17 Combination Product </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;Combination
Product&#148; shall mean </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD> 
<TD ALIGN="left" VALIGN="top">a single pharmaceutical formulation containing as its active ingredients either (i)&nbsp;a [***] or (ii)&nbsp;a [***], in each case together with one or more other therapeutically or prophylactically active ingredients
targeting an antigen other than the Target. For clarity, Combination Product in this Subsection a) also includes a [***] comprised of a [***] or [***] or [***] to [***] an[***], </TD></TR></TABLE> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 8 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD> 
<TD ALIGN="left" VALIGN="top">a combination therapy comprised of a [***] or [***] alone (or combined as described in a) above) and one or more other therapeutically or prophylactically active products, priced and sold in a single package containing
such multiple products or packaged separately but sold together for a single price, or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c)</TD> 
<TD ALIGN="left" VALIGN="top">a combination therapy comprised of a [***] alone (or combined as described in a) above) and a Companion Diagnostic, priced and sold in a single package containing such multiple products or packaged separately but sold
together for a single price, </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">in each case, including all dosage forms, formulations, presentations, line extensions, and package
configurations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.18 Commercially Reasonable Efforts </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;Commercially Reasonable Efforts&#148; shall mean such level of efforts required to carry out such obligation in a sustained manner consistent
with the efforts Roche or Pieris, as applicable, devotes at the same stage of development or commercialization, as applicable, for its own internally developed pharmaceutical products in a similar area with similar market potential, at a similar
stage of their product life taking into account the existence of other competitive products in the market place or under development, the proprietary position of the product, the regulatory structure involved, the anticipated profitability of the
product and other relevant factors. It is understood that such product potential may change from time to time based upon changing scientific, business and marketing and return on investment considerations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, Roche (and its Affiliates) does not always seek to market its own products in every country or seek to obtain regulatory approval in every country or
for every potential indication. As a result, the exercise of diligence by Roche is to be determined by judging Roche&#146;s commercially reasonable efforts, taken as a whole. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.19 Companion Diagnostic </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;Companion
Diagnostic&#148; shall mean any product that is used for predicting and/or monitoring the response of a human being to treatment with a Product (e.g. device, compound, kit, biomarker or service that contains a component that is used to detect or
quantify the presence or amount of an analyte in body or tissue that affects the pathogens of the disease). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.20 Composition of Matter Claim </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;Composition of Matter Claim&#148; shall mean, for a given Product in a given country of the Territory, a Valid Claim of a Patent Right that
Covers the active ingredient of a Product as a composition of matter. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.21 Compulsory Sublicense </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;Compulsory Sublicense&#148; shall mean a license or sublicense granted to a Third Party (a &#147;<B>Compulsory Sublicensee</B>&#148;), through
the order, decree or grant of a governmental authority having competent jurisdiction, authorizing such Third Party to manufacture, use, sell, offer for sale, import or export a Product in any country in the Territory. </P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 9 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.22 Confidential Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;Confidential Information&#148; shall mean any and all information, data or know-how (including Know-How), whether technical or non-technical,
oral or written, that is disclosed by one Party or its Affiliates (&#147;<B>Disclosing Party</B>&#148;) to the other Party or its Affiliates (&#147;<B>Receiving Party</B>&#148;). Confidential Information shall not include any information, data or
know-how that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="4%">&nbsp;</TD> 
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD> 
<TD ALIGN="left" VALIGN="top">was generally available to the public at the time of disclosure, or information that becomes available to the public after disclosure by the Disclosing Party other than through fault (whether by action or inaction) of
the Receiving Party or its Affiliates, </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="4%">&nbsp;</TD> 
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD> 
<TD ALIGN="left" VALIGN="top">can be evidenced by written records to have been already known to the Receiving Party or its Affiliates prior to its receipt from the Disclosing Party, </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="4%">&nbsp;</TD> 
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD> 
<TD ALIGN="left" VALIGN="top">is obtained at any time lawfully from a Third Party under circumstances permitting its use or disclosure, </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="4%">&nbsp;</TD> 
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD> 
<TD ALIGN="left" VALIGN="top">is developed independently by the Receiving Party or its Affiliates as evidenced by written records other than through knowledge of Confidential Information, </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="4%">&nbsp;</TD> 
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD> 
<TD ALIGN="left" VALIGN="top">is required to be disclosed by the Receiving Party or its Affiliates to comply with a court or administrative order, provided that the Receiving Party or its Affiliates furnishes prompt notice (in no event less than
three (3)&nbsp;days prior to such required disclosure) to the Disclosing Party to enable it to contest such disclosure, or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="4%">&nbsp;</TD> 
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(vi)</TD> 
<TD ALIGN="left" VALIGN="top">is approved in writing by the Disclosing Party for release by the Receiving Party. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The terms of this
Agreement shall be considered Confidential Information of the Parties. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.23 Continuation Election Notice </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;Continuation Election Notice&#148; shall mean the notice Pieris may provide to Roche under Section&nbsp;19.3.4. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.24 Control </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;Control&#148; shall mean (as
an adjective or as a verb including conjugations and variations such as &#147;Controls&#148; &#147;Controlled&#148; or &#147;Controlling&#148;) (a)&nbsp;with respect to Patent Rights and/or Know-How, the possession by a Party of the ability to grant
a license or sublicense of such Patent Rights and/or Know-How without violating the terms of any agreement or arrangement between such Party and any other party and (b)&nbsp;with respect to proprietary materials, the possession by a Party of the
ability to supply such proprietary materials to the other Party as provided herein without violating the terms of any agreement or arrangement between such Party and any other party. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.25 Cover </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;Cover&#148; shall mean (as an
adjective or as a verb including conjugations and variations such as &#147;Covered,&#148; &#147;Coverage&#148; or &#147;Covering&#148;) that the developing, making, using, offering for sale, promoting, selling, exporting or importing of a given
compound, formulation or product would infringe a Valid Claim in the absence of a license under the Patent Rights to which such Valid Claim pertains. The determination of whether a compound, formulation, process or product is Covered by a particular
Valid Claim shall be made on a country-by-country basis. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.26 Effective Date </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;Effective Date&#148; shall mean December&nbsp;8, 2015. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.27 Entry into Portfolio </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;Entry into
Portfolio&#148; shall mean, with regard to a Product, in the case of Roche, the decision by [***] to enter [***], and in the case of Pieris, with regards to a [***], the decision by its [***] to further develop such [***] following confirmation of
functionality in vitro. </P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 10 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.28 EU </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;EU&#148; shall mean the European Union and all its then-current member countries. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.29 Event </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;Event&#148; shall designate a
Product and a certain Indication for such Product. Each subsequent Event differentiates itself from the prior Event by either having a different Indication for the same Product, or by being a different Product with the same or a different
Indication. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.30 Expert </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;Expert&#148;
shall mean a person with no less than fifteen (15)&nbsp;years of pharmaceutical industry experience and expertise having occupied at least one senior position within a large pharmaceutical company relating to product development and/or licensing but
excluding any current or former employee or current consultant of either Party. Such person shall be fluent in the English language. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.31 FDA </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;FDA&#148; shall mean the Food and Drug Administration of the United States of America. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.32 FDCA </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;FDCA&#148; shall mean the Food,
Drug and Cosmetics Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.33 Field </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term
&#147;Field&#148; shall mean all biopharmaceutical, biomedical and diagnostic uses, including all therapeutic and prophylactic uses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.34 Filing
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;Filing&#148; shall mean the filing of an application by the FDA as defined in the FDCA and applicable regulations, or the equivalent
application to the equivalent agency in any other country or group of countries, the official approval of which is required before any lawful commercial sale or marketing of Products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.35 First Commercial Sale </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;First
Commercial Sale&#148; shall mean, on a country-by-country basis, the first invoiced sale of a Product to a Third Party by the Roche Group following the receipt of any Regulatory Approval required for the sale of such Product, or if no such
Regulatory Approval is required, the date of the first invoiced sale of a Product to a Third Party by the Roche Group in such country. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.36 FTE
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;FTE&#148; shall mean a full-time equivalent person-year, taking into consideration statutory holidays and paid annual leave. In no
circumstance can the work of any given person exceed one (1)&nbsp;FTE. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.37 FTE Rate </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;FTE Rate&#148; shall mean the amount of EUR [***] ([***] Euros) per FTE, on a fully burdened cost basis. Notwithstanding the foregoing, such FTE
Rate shall include the costs for [***] not to exceed EUR [***] ([***] Euros) during the Research Term. </P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 11 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.38 Generated </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;Generated&#148; means, with respect to a Product, that a plasmid construct was created and expressed in eukaryotic or bacterial cells. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.39 GLP Tox Study </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;GLP Tox Study&#148;
shall mean a study in accordance with the Good Laboratory Practice (GLP) to generate data by which the hazards and risks to users, consumers and third parties, including the environment, can be assessed for a product. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.40 Handle </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;Handle&#148; shall mean
preparing, filing, prosecuting (including interference and opposition proceedings) and maintaining (including interferences, reissue, re-examination, post-grant reviews, inter-parties reviews, derivation proceedings and opposition proceedings). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.41 HSR </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;HSR&#148; shall mean the
Hart-Scott-Rodino Antitrust Improvements Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.42 ICD </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;ICD&#148; shall mean the Tenth Revision of the International Classifications of Diseases and Related Health Problems of 2010. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.43 IFRS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;IFRS&#148; shall mean
International Financial Reporting Standards. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.44 Indication </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;Indication&#148; shall mean a distinct type of disease or medical condition in humans to which a Product is directed and eventually approved. To
distinguish one Indication from another Indication, the two Indications have to be (i)&nbsp;listed in two different blocks of the ICD (as a way of example, any neoplasm under C15 is in a different block from any neoplasm under block C16, whereas
C15.0 and C15.1 belong to the same block) and (ii)&nbsp;developed by Roche under separate Clinical Studies. Notwithstanding the foregoing, [***] and [***] shall be deemed to be two distinct Indications. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.45 Initiation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;Initiation&#148; or
&#147;Initiated&#148; shall mean, with respect to Clinical Studies, the date that a human is first dosed with the Product in a Clinical Study approved by (or allowed by) the respective Regulatory Authority, or, with respect to GLP Tox Studies, the
date an animal is first dosed with the Product in a GLP Tox Study approved by (or allowed by) the respective Regulatory Authority. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.46 Insolvency
Event </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;Insolvency Event&#148; shall mean circumstances under which a Party (i)&nbsp;has a receiver or similar officer appointed over all
or a material part of its assets or undertaking; (ii)&nbsp;passes a resolution for winding-up (other than a winding-up for the purpose of, or in connection with, any solvent amalgamation or reconstruction) or a court makes an order to that effect or
a court makes an order for administration (or any equivalent order in any jurisdiction); (iii)&nbsp;enters into any composition or arrangement with its creditors (other than relating to a solvent restructuring); (iv)&nbsp;ceases to carry on
business; (v)&nbsp;is unable to pay its debts as they become due in the ordinary course of business. </P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 12 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.47 Invention </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;Invention&#148; shall mean an invention that is conceived or reduced to practice in connection with any activity carried out pursuant to this
Agreement. Under this definition, an Invention may be made (including conceived) by employees of Pieris solely or jointly with a Third Party (a &#147;<B>Pieris Invention</B>&#148;), by employees of Roche solely or jointly with a Third Party (a
&#147;<B>Roche Invention</B>&#148;), or jointly by employees of Pieris and employees of Roche with or without a Third Party (a &#147;<B>Joint Invention</B>&#148;). Inventorship shall be determined in accordance with US patent laws. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.48 JP </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;JP&#148; shall mean Japan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.49 JRC </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;JRC&#148; shall mean the joint
research committee described in Section&nbsp;6. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.50 Know-How </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;Know-How&#148; shall mean data, knowledge and information, including materials, samples, chemical manufacturing data, toxicological data,
pharmacological data, preclinical data, assays, platforms, formulations, specifications, quality control testing data, that are necessary or useful for the discovery, manufacture, development or commercialization of Products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.51 Modified Binder </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;Modified
Binder&#148; shall mean a) a [***] alone or b) [***] conjugated and/or fused to each other (such as by a genetic linkage), in the case of a) with, and in the case of b) either with or without modification by conjugation and/or fusion to a moiety,
e.g., for [***]. Such [***] may include, without limitation, [***], including [***] based on Roche Technology. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.52 NDA </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;NDA&#148; shall mean a new drug application, including all necessary documents, data, and other information concerning a Product, required for
Regulatory Approval of the Product as a pharmaceutical product by the FDA or an equivalent application to the equivalent agency in any other country or group of countries (e.g. the marketing authorization application (MAA) in the EU). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.53 Net Sales </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;Net Sales&#148; shall
mean, for a Product in a particular period, the amount calculated by subtracting from the Sales of such Product for such period: (i)&nbsp;a lump sum deduction of [***] ([***]%) of Sales in lieu of those deductions that are not accounted for on a
Product-by-Product basis (<I>e.g.</I>, freight, postage charges, transportation insurance, packing materials for dispatch of goods, custom duties); (ii)&nbsp;actual uncollectible amounts accrued during such period and not already taken as a
gross-to-net deduction in accordance with the then currently used IFRS in the calculation of Sales of such Product for such period; (iii)&nbsp;credit card charges (including processing fees) accrued during such period on such Sales; and
(iv)&nbsp;government mandated fees and taxes and other government charges accrued (but excluding taxes based on the income of the selling party) during such period not already taken as a gross-to-net deduction in accordance with the then currently
used IFRS in the calculation of Sales of such Product for such period, including, for example, any fees, taxes or other charges that become due in connection with any healthcare reform, change in government pricing or discounting schemes, or other
action of a government or regulatory body. For clarity, no deductions taken in calculating Sales under Section&nbsp;1.71 may be taken a second time in calculating Net Sales. </P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 13 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.54 Party </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;Party&#148; shall mean Pieris or Roche, as the case may be, and &#147;Parties&#148; shall mean Pieris and Roche collectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.55 Patent Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;Patent Rights&#148;
shall mean all rights under any patent or patent application, in any country of the Territory, including any patents issuing on such patent application, and further including any substitution, extension or supplementary protection certificate,
reissue, reexamination, renewal, division, continuation or continuation-in-part of any of the foregoing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.56 Phase I Study </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;Phase I Study&#148; shall mean a human clinical trial in any country that would satisfy the requirements of 21 C.F.R. &#167; 312.21(a) (FDCA),
as amended from time to time, and the foreign equivalent thereof. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.57 Phase II Study </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;Phase II Study&#148; shall mean a human clinical trial, for which the primary endpoints include a determination of dose ranges and/or a
preliminary determination of efficacy in patients being studied as described in 21 C.F.R. &#167; 312.21(b) (FDCA), as amended from time to time, and the foreign equivalent thereof. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.58 Phase III Study </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;Phase III
Study&#148; shall mean a human clinical trial that is prospectively designed to demonstrate statistically whether a product is safe and effective for use in humans in a manner sufficient to obtain regulatory approval to market such product in
patients having the disease or condition being studied as described in 21 C.F.R. &#167; 312.21(c) (FDCA), as amended from time to time, and the foreign equivalent thereof. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.59 Phase-out Binder </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;Phase-out
Binder&#148; shall mean an Anticalin<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> discovered [***] that [***] the Target. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.60 Phase-out
Term </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;Phase-out Term&#148; shall mean the period beginning [***] provided that Roche has opted for [***] as described in
Section&nbsp;10.3.1, and ending [***] if Roche has paid [***] and beyond the [***], the [***], if applicable as per Sections 10.3.1. and 10.3.2. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.61
Pieris IP </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;Pieris IP&#148; shall mean Know-How and Patent Rights that Pieris owns or Controls (i)&nbsp;as of the Effective Date, which
include Patent Rights listed in Appendix 1.60; and (ii)&nbsp;during the Agreement Term that are necessary or useful for the discovery, manufacture, development or commercialization of an
Anticalin<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, or that are relating to Pieris Technology. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.62 Pieris Technology </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;Pieris Technology&#148; shall mean Anticalin Libraries, Anticalin Selection, Anticalin Expression and Anticalin Affinity Maturation methods.
</P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 14 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.63 Product </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;Product&#148; shall mean any product or composition containing at least one [***], regardless of their finished forms or formulations or
dosages. With regard to milestone and royalty payments, a Product shall differentiate itself from another Product by containing, in addition to at least [***], a [***] ([***]) as active ingredient that binds to [***]. Examples: 1) [***] developed as
separate products are considered the same Product; 2) a [***] and a [***] a pharmaceutically active molecule that [***] are considered two distinct Products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.64 Regulatory Approval </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;Regulatory
Approval&#148; shall mean any approvals, licenses, registrations or authorizations by Regulatory Authority, necessary for the sale of a Product in the Field in a regulatory jurisdiction in the Territory. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.65 Regulatory Authority </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;Regulatory
Authority&#148; shall mean any national, supranational (e.g., the European Commission, the Council of the European Union, the European Medicines Agency), regional, state or local regulatory agency, department, bureau, commission, council or other
governmental entity including the FDA, in each country involved in the granting of Regulatory Approval for the Product. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.66 Research Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;Research Plan&#148; shall mean the plan of research attached as Appendix 1.66 outlining the work expected to be performed by Pieris and Roche,
as such plan may be updated from time to time as permitted in this Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.67 Roche Group </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;Roche Group&#148; shall mean collectively Roche, its Affiliates and its Sublicensees. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.68 Roche IP </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;Roche IP&#148; shall mean
Know-How and Patent Rights that Roche owns or Controls as of the Effective Date and during the Agreement Term and that relate to Roche Technology. For purposes of clarity, the Patent Rights identified in Appendix 1.68 (&#147;<B>Excluded Patent
Rights</B>&#148;) are specifically excluded from the Roche IP. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.69 Roche Technology </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;Roche Technology&#148; shall mean Roche&#146;s [***] to be [***] with the [***] or [***] for [***]. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.70 Royalty Term </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;Royalty Term&#148;
shall mean, with respect to a Product and for a given country, the period of time commencing on the date of First Commercial Sale of the Product in such country and ending on the later of the date that is (a)&nbsp;[***] years after the date of the
First Commercial Sale of the Product in such country, or (b)&nbsp;the expiration of the last to expire Composition of Matter Claim of a patent owned or Controlled by [***] (or [***]) in such country Covering the use, import, offering for sale, or
sale of the Product. With regard to the countries of the EU, the [***] year period shall for each country begin at the earlier of (i)&nbsp;date of First Commercial Sale in the specific country or (ii)&nbsp;date of First Commercial Sale in [***]
([***]). For clarity, any Composition of Matter Claim Covering only [***] that [***] and which is comprised within Product shall not be relevant for determining the Royalty Term. </P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 15 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.71 Sales </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;Sales&#148; shall mean, for a Product in a particular period, the sum of (i)&nbsp;and (ii): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD> 
<TD ALIGN="left" VALIGN="top">the amount stated in the Roche Holding AG &#147;Sales&#148; line of its externally published audited consolidated financial statements with respect to such Product for such period (excluding sales to any Sublicensees
that are not Affiliates of Roche). This amount reflects the gross invoice price at which such Product was sold or otherwise disposed of (other than for use as clinical supplies or free samples) by Roche and its Affiliates to such Third Parties
(excluding sales to any Sublicensees that are not Affiliates of Roche) in such period reduced by gross-to-net deductions, if not previously deducted from such invoiced amount, taken in accordance with the then currently used IFRS, to the extent any
of such gross-to-net deductions are actually allowed. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">By way of example, the gross-to-net deductions taken in accordance
with IFRS as of the Effective Date include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="8%">&nbsp;</TD> 
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD> 
<TD ALIGN="left" VALIGN="top">credits, reserves or allowances granted for (i)&nbsp;damaged, outdated, returned, rejected, withdrawn or recalled Product, (ii)&nbsp;wastage replacement and short-shipments; (iii)&nbsp;billing errors and
(iv)&nbsp;indigent patient and similar programs (<I>e.g.</I>, price capitation); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="8%">&nbsp;</TD> 
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD> 
<TD ALIGN="left" VALIGN="top">governmental price reductions and government mandated rebates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="8%">&nbsp;</TD> 
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD> 
<TD ALIGN="left" VALIGN="top">chargebacks, including those granted to wholesalers, buying groups and retailers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="8%">&nbsp;</TD> 
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD> 
<TD ALIGN="left" VALIGN="top">customer rebates, including cash sales incentives for prompt payment, cash and volume discounts; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="8%">&nbsp;</TD> 
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD> 
<TD ALIGN="left" VALIGN="top">taxes and any other governmental charges or levies imposed upon or measured by the import, export, use, manufacture or sale of a Product (excluding income or franchise taxes). </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">For purposes of clarity, sales by Roche and its Affiliates to any Sublicensee shall be excluded from &#147;Sales&#148;, but a subsequent sale
to Third Parties by such Affiliate or Sublicensee shall be deemed a &#147;Sale&#148;. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD> 
<TD ALIGN="left" VALIGN="top">for Sublicensees that are not Roche Affiliates (and excluding Compulsory Sublicensees), the sales amounts reported to Roche and its Affiliates in accordance with the sublicensee contractual terms and their
then-currently used accounting standards. For the purpose of clarity, any such Sublicensee sales as reported to Roche in accordance with Compulsory Sublicense agreements shall be excluded from the sales amount. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.72 Selected Binder </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;Selected
Binder&#148; shall mean a [***] or [***] that originates from the pool of Binders discovered by screening any Pieris Anticalin Library, that may have undergone lead optimization, and is then selected by Roche for incorporation into a Product. At its
discretion, Roche can select [***] or [***] during the [***] or [***] and shall be free to [***] or [***] during such period, with such [***] to be [***] </P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 16 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.73 Sublicensee </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;Sublicensee&#148; shall mean an entity to which Roche has licensed any right (through one or multiple tiers), other than through a Compulsory
Sublicense, pursuant to this Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.74 Target </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;Target&#148; shall mean the biological target of a pharmacologically active drug compound. For this collaboration the [***] Target is [***] as
described in Appendix 1.74. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.75 Territory </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term
&#147;Territory&#148; shall mean all countries of the world. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.76 Third Party </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;Third Party&#148; shall mean a person or entity other than (i)&nbsp;Pieris or any of its Affiliates or (ii)&nbsp;a member of the Roche Group.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.77 US </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;US&#148; shall mean the
United States of America and its territories and possessions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.78 Valid Claim </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;Valid Claim&#148; shall mean a claim in any unexpired and issued Patent Rights that has not been disclaimed, revoked or held invalid by a final
non-appealable decision of a court of competent jurisdiction or government agency. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1.79 Additional Definitions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of the following definitions is set forth in the Section of this Agreement indicated below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

 
<TR> 
<TD WIDTH="82%"></TD> 
<TD VALIGN="bottom" WIDTH="4%"></TD> 
<TD WIDTH="14%"></TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:8pt"> 
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Definition</B></P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Section</B></P></TD></TR>

 
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Accounting Period</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">11.1</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Acquired Party</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">19.2.3</TD></TR> 
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Alliance Director</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">6.8</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Annual Exclusive Target Access Fee</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">10.3.1</TD></TR> 
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Bankruptcy Code</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">20</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">2.4</TD></TR> 
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Breaching Party</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">19.2.1</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Chairperson</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">6.2</TD></TR> 
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Chugai</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">1.1</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Companion Diagnostic Product</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">10.4</TD></TR> 
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Compulsory Sublicensee</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">1.21</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Development Event</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">10.4&nbsp;(in&nbsp;table)</TD></TR> 
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Disclosing Party</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">1.22</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Excluded Patent Rights</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">1.68</TD></TR> 
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Expert Committee</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">10.7</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">First Sales Based Event</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">10.5</TD></TR> 
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Foundation</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">1.1</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Indemnified Party</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">16.3</TD></TR> 
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Indemnifying Party</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">16.3</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Joint Invention</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">1.47</TD></TR> 
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Members</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">6.2</TD></TR></TABLE> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 17 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

 
<TR> 
<TD WIDTH="86%"></TD> 
<TD VALIGN="bottom" WIDTH="4%"></TD> 
<TD WIDTH="10%"></TD></TR>
 
<TR STYLE="font-family:Times New Roman; font-size:8pt"> 
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Definition</B></P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Section</B></P></TD></TR>

 
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Non-Acquired Party</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">19.2.3</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Non-Breaching Party</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">19.2.1</TD></TR> 
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Patent Term Extensions</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">14.11</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Payment Currency</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">11.3</TD></TR> 
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Peremptory Notice Period</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">19.2.1</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">[***]</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">10.3.2</TD></TR> 
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Pieris Invention</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">1.47</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Progress Reports</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">3.1.5</TD></TR> 
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Publishing Notice</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">18.4</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Publishing Party</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">18.4</TD></TR> 
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Receiving Party</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">1.22</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Reference Product Sponsor</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">14.10</TD></TR> 
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Relative Commercial Value</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">10.7</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Research Records</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">3.1.6</TD></TR> 
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Research Term</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">3.1.4</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Roche Invention</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">1.47</TD></TR> 
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Roche Valid Claim</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">19.3.4 (b)</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Samples</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">19.3.4&nbsp;(b)</TD></TR> 
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">SEC</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">1.9</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Second Sales Based Event</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">10.5</TD></TR> 
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Sensitive Information</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">19.2.3</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">SPCs</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">14.11</TD></TR> 
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Stand-alone Diagnostic Product</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">10.4</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Third Sales Based Event</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">10.5</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Grant of License </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.1 Research Licenses </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Roche grants to Pieris during the
Research Term a non-exclusive right and license under Roche IP that are necessary or useful for the discovery, manufacture or development of [***] solely to enable Pieris to perform the activities contemplated under the Research Plan under this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pieris grants to Roche during the Agreement Term an exclusive (even as to Pieris except for activities performed under the Research Plan and,
if applicable, [***] for Roche) right and license under Pieris IP that are necessary or useful for the discovery, manufacture or development of [***] and Products, in particular to enable Roche to identify and evaluate [***] in order to enable
selection of [***]. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.2 Commercial License to Roche </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pieris hereby grants to Roche an exclusive (even as to Pieris) right and license, including the right to sublicense through multiple tiers, under Pieris&#146;
interest in the Pieris IP to research, have researched, develop, have developed, register, have registered, use, have used, make, have made, import, have imported, export, have exported, market, have marketed, distribute, have distributed, sell and
have sold Products in the Field in the Territory. </P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 18 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.3 Sublicense </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Roche shall have the right to sublicense or subcontract (through multiple tiers); provided, however, that in the event of such sublicensing, (a)&nbsp;such
Sublicensees will be subject to the same confidentiality and diligence obligations Roche has hereunder, and (b)&nbsp;Roche will remain liable for all the terms and conditions of this Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2.4 License to Pieris after Phase-out Term </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After
expiration of the Phase-out Term and with respect to Target, Roche grants Pieris (subject to Roche&#146;s right of first negotiation as defined below) a non-exclusive license, including the right to sublicense through multiple tiers, under
Roche&#146;s Patent Rights on Inventions made under the Agreement. Said license shall be limited to such Inventions (a)&nbsp;made (including conceived) during the time period starting at the Effective Date and ending [***] and (b)&nbsp;related to
[***] to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD> 
<TD ALIGN="left" VALIGN="top">Select binders from the hits obtained [***], performed after [***], of the Anticalin Libraries, that &#150; per each individual binder &#150; contain [***] in the amino acid positions that Pieris randomizes in its
Anticalin Libraries (in comparison to the amino acid sequence of the respective wild type lipocalin; for clarity, this means [***] depending on the Anticalin Library used) as compared to [***] and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD> 
<TD ALIGN="left" VALIGN="top">On the basis of binders obtained under (i)&nbsp;above, research, have researched, develop, have developed, register, have registered, use, have used, make, have made, import, have imported, export, have exported,
market, have marketed, distribute, have distributed, sell and have sold products that, in addition to [***] and which would infringe such Roche&#146;s Patent Rights but for a license granted hereunder (&#147;<B>[***]</B>&#148;), in the Field in the
Territory. [***] may not bind to the [***] as [***] for which [***] has [***] and is developing using Commercially Reasonable Efforts at the time Pieris initiates an independent screening campaign as described under (i)&nbsp;above for a [***].
Pieris shall have the right to make a written query to Roche&#146;s alliance manager (to be communicated by Roche in the annual reports under Section&nbsp;6.11) in order to find out if [***] has [***] with regard to a [***], which query shall be
answered within thirty (30)&nbsp;days. For clarity, the license granted by Roche to Pieris for a [***] shall be maintained even in the situation where Roche has, subsequent to Roche granting the license hereunder, [***], provided, however, that
Pieris has used Commercially Reasonable Efforts to [***]. For further clarity, the above license is limited to [***] and does not include [***]. Pieris shall inform Roche in writing about all [***] for which it has reached [***] within thirty
(30)&nbsp;days after such [***] has been reached. Furthermore, Pieris shall annually inform Roche on the development progress of such [***] until completion of the first Phase II Study. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Example 1: If Pieris makes a query for a specific [***] (i.e., [***]), and Roche has reached [***], then no license is granted to Pieris. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Example 2: If Pieris makes a query for a specific [***] (i.e. [***]), and Roche has reached [***] (i.e., [***]) that [***], then no license is
granted to Pieris. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, the above license is subject to Roche&#146;s right of first negotiation along the following lines: (i)&nbsp;if either Pieris
decides to seek a licensing partnership with a third party with regards to a [***], or to sell such [***] to a third party (for clarity, a Change of Control of Pieris shall not be deemed a sale of such [***]), or a [***] that has not been partnered
or sold has completed the first Phase II Study, it shall provide written notice of such intent to Roche; (ii)&nbsp;Roche shall then have [***] to request access to any information Pieris&#146; has with regard to such [***]; (iii)&nbsp;in case Roche
does request such access, then Roche shall have [***] after Pieris has granted to Roche </P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 19 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
access to the relevant and complete files and provided corresponding information to Roche to decide whether it wants to develop and commercialize such [***] itself and to provide a corresponding
written notice to Pieris of its intent to do so; (iv)&nbsp;in case Roche does provide such written notice, then Roche shall have the exclusive right to negotiate an agreement with Pieris with regard to such [***], under terms to be negotiated in
good faith and such agreement to be put in writing within [***] of Roche&#146;s written notification to Pieris of its intent to develop and commercialize such [***] itself (hereinafter called &#147;Negotiation Period&#148;). If Roche and Pieris fail
to agree upon the terms and conditions for such agreement during the Negotiation Period, Pieris will be free to enter into a transaction regarding such [***] with any Third Party; provided that Pieris shall not enter into an agreement with any Third
Party on financial terms and conditions that are more favourable for the Third Party when taken in their totality than the terms and conditions last offered in writing by Roche to Pieris during the Negotiation Period. Notwithstanding the foregoing,
if Pieris intends to enter into a partnership to Generate [***] (i.e., that have not been Generated at the time of notification from Pieris), Roche shall only have [***] from receipt of such notification under (i)&nbsp;to assess and decide if it
wants to request negotiations under (iv). In other words, the procedures foreseen in (ii)&nbsp;and (iii)&nbsp;of this paragraph shall in total [***]. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Research Collaboration </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1.1 Scope
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The execution of the Research Plan shall begin on January 1, 2016. During the Research Term, Pieris commits, subject to FTE funding by Roche, to an
average of [***] as specified in the Research Plan and adjusted as necessary by the JRC from time to time, allowing the generation and testing of [***] against the Target, the generation and testing of [***] and Products, as well as any other
activities to be performed according to the Research Plan. The criteria for successfully completing the Research Plan and handing over the deliverables are defined in the Research Plan. The activities conducted in connection with the Research Plan
will be overseen by the JRC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1.2 Diligent Efforts </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Roche and Pieris shall each use Commercially Reasonable Efforts to perform their respective tasks and obligations in conducting all activities ascribed to it
in the then-current Research Plan, in accordance with the time parameters set forth therein. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1.3 Research Plan </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Parties will conduct the research in accordance with the Research Plan. In alignment with Section&nbsp;6.3, the Research Plan will be updated as needed by
the JRC, with such updates to be documented in an updated Research Plan as part of the applicable JRC Minutes. The Research Plan will set forth (i)&nbsp;the scope of the research and the resources that will be dedicated to the activities
contemplated within the scope of the research, including the responsibilities of each Party, (ii)&nbsp;specific objectives for each Research Plan task, which objectives will be updated or amended, as appropriate, by the JRC as research progresses,
and (iii)&nbsp;budgets for such activities. </P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 20 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1.4 Research Term </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Research Term shall commence on January 1, 2016 and shall continue for [***] unless extended by Roche by providing written notice to Pieris no later than
ninety (90) days prior to the end of the initial term and subject to further FTE funding for a period up to [***]. If at the end of the Research Term (including any extension) the original objectives of the Research Plan are not met and Roche could
not choose [***] for product development, the Parties shall agree on whether to further extend the Research Term and the share of funding by each Party. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1.5 Progress Reports </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At least quarterly
during the Research Term, Pieris shall have the obligation to prepare and provide to the JRC a detailed written report summarizing the progress of the work performed by Pieris under the Research Plan during the preceding Calendar Quarter. Promptly
upon expiry of the Research Term, Pieris shall provide a final written report summarizing its activities under the Research Plan and the results thereof. Upon the written request of Roche and not more than once in each Calendar Year, Pieris shall
permit Roche, at Roche&#146;s expense, to have access during normal business hours to those records of Pieris that may be necessary to verify the basis for any payments hereunder. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1.6 Research Records </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each Party shall
maintain records regarding the execution of the Research Plan (or cause such records to be maintained) in sufficient detail and in good scientific manner as will properly reflect all work done and results achieved by or on behalf of such Party in
the performance of the Research Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1.7 Work on Target by Pieris </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the Research Term and, if applicable, the [***], Pieris shall work exclusively with Roche to identify and discover molecules that inhibit or
specifically bind to the Target. For the avoidance of doubt, this obligation also precludes Pieris from working on the Target under its own independent research. In case Pieris undergoes a Change of Control and the Change of Control Group has or
puts in place a research program targeting the Target, or if Pieris takes over control of a Third Party having such a research program, then Pieris shall put or have put in place appropriate fire walls in order to avoid any spillover of information
regarding the Research Plan and associated Progress Reports, Research Records and Confidential Information received from Roche under this Agreement outside of the organisation of Pieris that exists before such Change of Control or take over takes
place. Pieris may not perform work on Pieris Technology with regard to Target except as provided for under this Agreement (including, for clarity, as described under Section&nbsp;2.4). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Diligence </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.1 In General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Roche and Pieris shall use Commercially Reasonable Efforts to perform their respective activities contemplated by this Agreement or as may be agreed upon in
any subsequent written agreements with respect to the subject matter hereof, including but not limited to any activities under the Research Plan. Specifically, Roche agrees to use Commercially Reasonable Efforts to pursue development and
commercialization of Products in the Field in the Territory, which </P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 21 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
minimally shall require that Roche shall seek to market at least one Product in [***] and in [***] ([***]). Notwithstanding anything to the contrary in this Agreement, Roche shall be deemed to
not be using Commercially Reasonable Efforts, if, for whatever reason, it completely ceases all research, development or commercialization activities on all Products for a period longer than [***] during the Agreement Term. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.2 Diligence of Roche prior to Initiation of Phase III Study </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If Roche or any of its Affiliates (i)&nbsp;acquires (e.g., by way of in-license or acquisition) a product targeting the Target for which [***], or
(ii)&nbsp;internally develops a product targeting the Target for which [***], and that for (i)&nbsp;and (ii)&nbsp;does not utilize Pieris Technology, then, for as long as such competing product is more advanced than the first Product, Roche shall
and shall ensure that its Affiliates with regards to any first Product commit to the following timelines: (a)&nbsp;Initiation of first GLP Tox Study within [***], (b)&nbsp;Initiation of first Phase I Study within [***], (c)&nbsp;Initiation of first
Phase II Study within [***], or, if such timelines are not deemed appropriate by Roche, and Roche provides acceptable reasons for delays as reasonably accepted by Pieris, such timelines may be extended by mutual written agreement. The diligence
obligation under this Section&nbsp;4.2 expires when such acquired or internally developed product is terminated. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.3 Limits </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For clarity, the foregoing limitations on acquiring or internally developing products targeting the Target as described in Section&nbsp;4.2 shall not apply to
[***] of the [***] or [***] or that are [***] or [***], for as long as [***]. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Development </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.1 Development by Roche </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After a [***] has been
transferred from Pieris to Roche as specified in the Research Plan, Roche, at its sole cost, shall be responsible for pursuing pre-clinical and clinical development of Products, subject to the terms of this Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.2 Provision of Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pieris shall disclose and
make available to Roche (i)&nbsp;all data and information developed under the Research Plan, and (ii)&nbsp;all additional data and information that Pieris reasonably believes are necessary to conduct development of Products. Pieris, through the JRC,
shall answer any questions reasonably posed and provide any information reasonably requested. Notwithstanding the foregoing, Pieris shall not be obligated to disclose any confidential information received from a Third Party to Roche. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Governance </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.1 Joint Research Committee </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Within sixty (60)&nbsp;days after the Effective Date of this Agreement, the Parties shall establish a JRC to oversee the development activities under this
Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.2 Members </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The JRC shall be composed of
four (4)&nbsp;persons (&#147;<B>Members</B>&#148;). Roche and Pieris each shall be entitled to appoint two (2)&nbsp;Members with appropriate seniority and functional expertise. Each Party may replace any of its Members and appoint a person to fill
the vacancy arising from each such replacement. A Party that replaces a Member shall notify the other Party at least ten (10)&nbsp;days prior to the next scheduled meeting of the JRC. Both Parties shall use reasonable efforts
</P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 22 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to keep an appropriate level of continuity in representation. Both Parties may invite a reasonable number of additional experts and/or advisors to attend part or the whole JRC meeting with prior
notification to the JRC. Members may be represented at any meeting by another person designated by the absent Member. The JRC shall be chaired by a Roche Member (&#147;<B>Chairperson</B>&#148;). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.3 Responsibilities of the JRC </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The JRC shall have the
responsibility and authority to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD> 
<TD ALIGN="left" VALIGN="top">approve the Research Plan; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD> 
<TD ALIGN="left" VALIGN="top">review and revise the Research Plan; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c)</TD> 
<TD ALIGN="left" VALIGN="top">oversee the execution of the Research Plan; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="4%" VALIGN="top" ALIGN="left">d)</TD> 
<TD ALIGN="left" VALIGN="top">establish timelines and criteria for decision points; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="4%" VALIGN="top" ALIGN="left">e)</TD> 
<TD ALIGN="left" VALIGN="top">determine whether success- and other criteria have been met; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="4%" VALIGN="top" ALIGN="left">f)</TD> 
<TD ALIGN="left" VALIGN="top">evaluate [***] </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="4%" VALIGN="top" ALIGN="left">g)</TD> 
<TD ALIGN="left" VALIGN="top">review the efforts of the Parties and allocate those resources for the Research Plan (including the budget); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="4%" VALIGN="top" ALIGN="left">h)</TD> 
<TD ALIGN="left" VALIGN="top">identify and agree on the appropriate resources (including FTE staffing requirements) necessary to conduct the Research Plan; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="4%" VALIGN="top" ALIGN="left">i)</TD> 
<TD ALIGN="left" VALIGN="top">establish a touch point site or similar tool to enable secured exchange of data generated under the Research Plan </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="4%" VALIGN="top" ALIGN="left">j)</TD> 
<TD ALIGN="left" VALIGN="top">monitor and implement the transfer of the [***], both in terms of material available at Pieris and the corresponding amino acid and nucleic acid sequences, and any associated data generated under the Research Plan to
Roche; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="4%" VALIGN="top" ALIGN="left">k)</TD> 
<TD ALIGN="left" VALIGN="top">monitor the number of FTE funding and adaptation of such number as necessary as set forth in Section&nbsp;3.1.1; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="4%" VALIGN="top" ALIGN="left">l)</TD> 
<TD ALIGN="left" VALIGN="top">recommend action items to its respective decision making bodies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="4%" VALIGN="top" ALIGN="left">m)</TD> 
<TD ALIGN="left" VALIGN="top">in a JRC meeting towards the end of the Research Term, list the materials and information to be provided by Pieris to Roche according to Section&nbsp;10.3.1; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="4%" VALIGN="top" ALIGN="left">n)</TD> 
<TD ALIGN="left" VALIGN="top">attempt to resolve any disputes on an informal basis; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="4%" VALIGN="top" ALIGN="left">o)</TD> 
<TD ALIGN="left" VALIGN="top">determine the mechanism of project information exchange, including project team meetings. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The JRC shall have
no responsibility and authority other than that expressly set forth in this section or otherwise expressly provided in this Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.4 Meetings
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Chairperson or his/her delegate is responsible for sending invitations and agendas for all JRC meetings to all Members at least ten (10)&nbsp;days
before the next scheduled meeting of the JRC. The venue for the meetings shall be agreed by the JRC. The JRC shall hold meetings at least twice per calendar year, either in person or by tele-/video-conference (but at least once per year in person),
and in any case as frequently as the Members of the JRC may agree shall be necessary, but not more than four times a year. The Alliance Director of each Party may attend the JRC meetings as a permanent participant and may be a JRC Member. </P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 23 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.5 Minutes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Chairperson is responsible for designating a Member to record in reasonable detail and circulate draft minutes of JRC meetings to all members of the JRC
for comment and review within twenty (20)&nbsp;days after the relevant meeting. The Members of the JRC shall have ten (10)&nbsp;days to provide comments. The Party preparing the minutes shall incorporate timely received comments and distribute
finalized minutes to all Members of the JRC within thirty-five (35)&nbsp;days of the relevant meeting. The Chairperson approves the final version of the minutes before its distribution. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.6 Decisions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.6.1 Decision Making
Authority </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The JRC shall decide matters within its responsibilities set forth in Section&nbsp;6.3. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.6.2 Consensus; Good Faith </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Members of the
JRC shall act in good faith to cooperate with one another and seek agreement with respect to issues to be decided by the JRC. The Parties shall endeavor to make decisions by consensus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.6.3 Failure to Reach Consensus </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the JRC is
unable to decide a matter by consensus, then Roche shall have the final decision authority on any matter. However, a unilateral decision by Roche shall not result in any material change of the day to day use or operational allocation of Pieris&#146;
personnel, equipment and resources, or in any material increase in the overall level of resources to be committed by Pieris to the Research Plan unless Roche compensates Pieris accordingly. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.7 Information Exchange </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pieris and Roche shall exchange
the information in relation to their activities under the Research Plan through the JRC and Pieris and Roche may ask reasonable questions in relation to the above information and offer advice in relation thereto. The JRC may determine other routes
of information exchange. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.8 Alliance Director </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each
Party shall appoint one person to be the point of contact within each Party with responsibility for facilitating communication and collaboration between the Parties (each, an &#147;<B>Alliance Director</B>&#148;). The Alliance Directors may
participate in the JRC meetings. The Alliance Directors shall facilitate resolution of potential and pending issues and potential disputes to enable the JRC to reach consensus and avert escalation of such issues or potential disputes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.9 Limitations of Authority </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The JRC shall have no
authority to amend or waive any terms of this Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.10 Expenses </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each Party shall be responsible for its own expenses including travel and accommodation costs incurred in connection with the JRC. </P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 24 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6.11 Lifetime </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The JRC shall exist until the [***]. Thereafter, Roche shall provide Pieris annual reports describing in reasonable detail the development and
commercialization progress of the Product(s), including [***] in Roche&#146;s opinion (these include activities related to milestone achievements under this Agreement). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Supply </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.1 Clinical Supply of Product(s) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Roche shall be responsible at its own expense for the manufacture and supply of clinical supplies of the Product(s). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.2 Commercial Supply of Product(s) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Roche shall be
solely and exclusively responsible at its own expense for the commercial manufacture and commercial supply of Product(s) for sale in the Territory, either by itself or through Third Parties. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7.3 Provision of Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pieris shall disclose and
make available to Roche all additional data and information that Pieris reasonably believes are necessary or useful to manufacture and supply the Product(s). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Regulatory </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8.1 Responsibility </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Roche, at its sole cost, shall pursue all regulatory affairs related to Product(s) in the Territory including the preparation and filing of applications for
regulatory approval, as well as any or all governmental approvals required to develop, have developed, make, have made, use, have used, manufacture, have manufactured, import, have imported, sell and have sold Products. Roche shall be responsible
for pursuing, compiling and submitting all regulatory filing documentation, and for interacting with regulatory agencies, for all Products in all countries in the Territory. Roche or its Affiliates shall own and file in their discretion all
regulatory filings and regulatory approvals for all Products in all countries of the Territory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Roche, at its sole cost, shall report to appropriate
authorities in accordance with local requirements all adverse events related to use of the Products in the Territory. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Commercialization </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9.1 Responsibility </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Roche, at its own expense, shall have
sole responsibility and decision making authority for the marketing, promotion, sale and distribution of Products in the Territory. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9.2 Updates to
Pieris </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon request of Pieris, Roche shall update Pieris regarding the commercialization of the Product in the Territory in the Field by Roche, its
Affiliates and Sublicensees. If Pieris requests an update, Roche shall provide a high level summary, in writing and/or through a meeting (face to face/ tele-presence/videoconference or telephone). Pieris shall not request an update more frequently
than [***]. </P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 25 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Payment </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.1 Initiation Payment </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Within thirty (30)&nbsp;days
after the Effective Date and receipt of an invoice from Pieris, Roche shall pay to Pieris six and a half million Swiss francs (CHF 6,500,000). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.2
Research Costs </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the Research Term, Roche shall fund the work to be performed at Pieris for the Research Plan at the FTE Rate as specified in the
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Roche shall pay to Pieris such work to be performed during the Research Term, [***], within [***] after receiving a corresponding invoice from
Pieris, corresponding to the [***] for such [***] according to the Research Plan (as it may be amended from time to time through the JRC). Within thirty (30)&nbsp;days after the end of each Calendar Quarter during the Research Term, Pieris shall
provide to Roche a document specifying [***] and [***] incurred by Pieris during such Calendar Quarter. Any overpayment from Roche shall be credited to the invoice for the next quarter. Any underpayment from Roche shall be added to the invoice for
the next quarter. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.3 [***] Access Fee and [***] Extension Fee </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.3.1 Annual Exclusive Target Access Fee </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When
(i)&nbsp;all [***] have been transferred to Roche, including material available at Pieris, information on the corresponding amino acid and nucleic acid sequences, and any relevant associated data generated under the Research Plan in accordance with
the final report under Section&nbsp;3.1.5 (excluding the [***]) and as specified by the JRC in accordance with Section&nbsp;6.3 (m), and Roche has confirmed the receipt of all materials, information and the final report as per 3.1.5 (such
confirmation not to be unduly delayed), and (ii)&nbsp;[***] has ended, then Roche shall have [***] to exercise its option to [***] as specified in [***] by giving written notice to Pieris. If Roche provides such written notice, it shall pay to
Pieris an [***] access fee as specified in this Section (&#147;<B>[***]</B> Access Fee&#148;). In case Roche opts for such [***], then Roche shall have the right to terminate such [***] at the end of each anniversary date of the end of the Research
Term, by providing written notice to Pieris at the latest [***] prior to such anniversary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The [***] Access Fee shall be, if applicable: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD> 
<TD ALIGN="left" VALIGN="top">for each of the [***] following the end of the Research Term: </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">CHF [***]. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD> 
<TD ALIGN="left" VALIGN="top">for each of the [***] following the end of the Research Term: </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">CHF [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.3.2 [***] Extension Fee </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If Roche has opted
for [***] as described in Section&nbsp;10.3.1 above, then Roche shall pay to Pieris an additional [***] extension fee (&#147;<B>[***]</B> Extension Fee&#148;) if (i)&nbsp;Roche does not terminate [***] as described in Section&nbsp;10.3.1 before the
[***] of the end of the [***] and (ii)&nbsp;Roche has [***] with regard to the first Product reaching this development stage within [***] of expiry of the [***]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The [***] Extension Fee shall be, if applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD> 
<TD ALIGN="left" VALIGN="top">for the [***] following the end of the Research Term: </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">CHF [***]. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD> 
<TD ALIGN="left" VALIGN="top">for the [***] following the end of the Research Term: </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">CHF [***]. </P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 26 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The [***] Extension Fee will be paid in addition to the [***] Access Fee (if applicable) for the [***]
following the end of the [***]. Roche shall pay to Pieris amounts due under this Section&nbsp;10.3 within [***] from receipt of the correct invoice from Pieris. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.4 Development Event Payments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Products Generated
during [***] (the [***] shall be deemed to be (i)&nbsp;[***], and (ii)&nbsp;for any other Product as long as specified in Section&nbsp;1.60, but in any event at least [***]), Roche shall pay to Pieris the following one-time payments at the following
respective amounts for the applicable Development Events (as listed in the table below) upon reaching the respective Development Event: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

 
<TR> 
<TD WIDTH="67%"></TD> 
<TD VALIGN="bottom" WIDTH="10%"></TD> 
<TD></TD> 
<TD VALIGN="bottom" WIDTH="10%"></TD> 
<TD></TD> 
<TD VALIGN="bottom" WIDTH="10%"></TD> 
<TD></TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:8pt"> 
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:66.85pt; font-size:8pt; font-family:Times New Roman"><B>Development Event</B></P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">first&nbsp;Event<br>([***]&nbsp;CHF)</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">[***]<br>([***]&nbsp;CHF)</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">[***]<br>([***]&nbsp;CHF)</TD></TR>

 
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initiation of GLP Tox Study</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">[***]</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">[***]</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initiation of Phase I Study</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">[***]</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">[***]</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR> 
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initiation of Phase II Study</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">[***]</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">[***]</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initiation of Phase III Study</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">[***]</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">[***]</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR> 
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NDA Filing [***]</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">[***]</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">[***]</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NDA Filing [***]</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">[***]</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">[***]</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR> 
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NDA Filing [***]</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">[***]</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">[***]</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First Commercial Sale [***]</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">[***]</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">[***]</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR> 
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First Commercial Sale [***]</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">[***]</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">[***]</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First Commercial Sale [***]</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">[***]</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">[***]</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR> 
<TR STYLE="font-size:1px; "> 
<TD VALIGN="bottom"></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR> 
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">[***]</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">[***]</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR> 
<TR STYLE="font-size:1px; "> 
<TD VALIGN="bottom"></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD> 
<TD ALIGN="left" VALIGN="top">Payments for a [***] of a Product shall be payable upon achievement of Regulatory Approval in the respective portion of the Territory. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amounts specified in the table immediately above shall be reduced by [***] for Products Generated during the [***] Phase-out Term. For clarity, the
respective Development Event shall be deemed to have been paid in full, even if such reduction applies. For Products Generated later than [***] Phase-out Term, no milestone payments shall be paid. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For clarity, the total potential development event payments for a first Event shall not exceed [***] Swiss francs (CHF [***]), the total potential development
event payments for each of a [***] shall not exceed [***] Swiss francs (CHF [***]), the total potential development event payments for each of a [***] shall not exceed [***] Swiss francs (CHF [***]), and in no case shall the total development event
payments paid to Pieris under this Section exceed [***] Swiss francs (CHF [***]). In case[***] and/or [***] is not [***], then the [***]and/or [***] becomes [***] and/or [***] with regard to[***] to the extent of the [***], and [***] with regard to
the [***] and/or [***]. Payments with regards to a Development Event for a [***], respectively, are payable only once under this Agreement, upon the first occurrence of the applicable Development Event irrespective of the number of times such
Development Event may subsequently occur through the development of a subsequent Product and/or Indication. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Example: [***]. </P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 27 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon reaching Development Events, Roche shall timely notify Pieris and Development Event payments shall be
paid by Roche to Pieris within [***] from occurrence of the applicable event and receipt of a correct invoice from Pieris. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding anything
contained in this Section&nbsp;10.4, no development event payments shall be paid to Pieris in the event that a Product is itself developed as a companion diagnostic, i.e. for predicting and/or monitoring the response of a human being to treatment
with another Product (e.g. as a biomarker that is used to detect or quantify the presence or amount of Target in body or tissue; such Product a &#147;<B>Companion Diagnostic Product</B>&#148;). The same rule shall apply (no development event
payments) in case a Product is developed as a stand-alone diagnostic product, i.e. for detecting the presence and/or quantifying the amount of Target in body fluids or tissue (&#147;<B>Stand-alone Diagnostic Product</B>&#148;). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.5 Sales Based Events </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Roche shall pay to Pieris the
following one-time sales based event payments as specified in the table below (First Sales Based Event, Second Sales Based Event, Third Sales Based Event) up to a total of [***] Swiss francs (CHF [***]) at the following respective amounts for the
applicable events for the first Product to achieve the following levels of Net Sales: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

 
<TR> 
<TD WIDTH="66%"></TD> 
<TD VALIGN="bottom" WIDTH="16%"></TD> 
<TD></TD> 
<TD VALIGN="bottom" WIDTH="16%"></TD> 
<TD></TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:8pt"> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Payment</B></TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:8pt"> 
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:68.40pt; font-size:8pt; font-family:Times New Roman"><B>Net Sales Threshold</B></P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>if Product is<BR>Generated&nbsp;during<BR>[***]*</B></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>if Product is<BR>Generated&nbsp;during<BR>[***]*</B></TD></TR>

 
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top">First Calendar Year in which worldwide calendar year Net Sales of a Product exceed CHF [***] (&#147;<B>First Sales Based Event</B>&#148;)</TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom">CHF&nbsp;[***]</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="bottom">CHF&nbsp;[***]</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top">First Calendar Year in which worldwide calendar year Net Sales of a Product exceed CHF [***] (&#147;<B>Second Sales Based Event</B>&#148;)</TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom">CHF&nbsp;[***]</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="bottom">CHF&nbsp;[***]</TD></TR> 
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top">First Calendar Year in which worldwide calendar year Net Sales of a Product exceed CHF [***] (&#147;<B>Third Sales Based Event</B>&#148;)</TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom">CHF&nbsp;[***]</TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="bottom">CHF&nbsp;[***]</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD> 
<TD ALIGN="left" VALIGN="top">The [***] shall be deemed to be (i)&nbsp;[***] for [***], and (ii)&nbsp;for any other Product as long as specified in Section&nbsp;1.60, but in any event at least [***]. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Products Generated later than [***] Phase-out Term, no milestone payments shall be paid. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of the sales based event payments shall be paid no more than once during the Agreement Term, at first occurrence of the event for the Product in the
Territory first reaching the respective Net Sales Threshold, irrespective of whether or not the previous sales based event payment was triggered by the same or by a different Product, and shall be non-refundable, and shall be paid within [***] after
the end of the Calendar Year in which the event first occurs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding anything contained in this Section&nbsp;10.5, no sales event payments shall
be paid to Pieris in the event that a Product is itself developed, used and commercialized as a Companion Diagnostic Product or as a Stand-alone Diagnostic Product. </P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 28 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.6 Royalty Payments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.6.1 Royalty Term </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Royalties shall be payable
by Roche on Net Sales of Products on a Product-by-Product and country-by-country basis until the expiry of the Royalty Term. Thereafter, the licenses granted to Roche shall be fully paid up, irrevocable, and royalty-free. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.6.2 Royalty Rates </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Roche shall, on a
Product-by-Product basis, for any Product that was Generated during [***] (the [***] shall be deemed to be (i)&nbsp;[***] for [***], and (ii)&nbsp;for any other Product as long as specified in Section&nbsp;1.60, but in any event at least [***]), pay
to Pieris royalties by applying the following royalty rates on Calendar Year Net Sales of a given Product in the Territory as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

 
<TR> 
<TD WIDTH="83%"></TD> 
<TD VALIGN="bottom" WIDTH="16%"></TD> 
<TD></TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:8pt"> 
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Tier of Calendar Year</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:105.70pt; font-size:8pt; font-family:Times New Roman"><B>Net Sales in CHF of a Product:</B></P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent&nbsp;(%)&nbsp;of</B><br><B>Net Sales:</B></TD></TR>

 
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Up to CHF [***] Net Sales</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom">[***]</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">More than CHF [***] Net Sales and up to CHF [***] Net Sales</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom">[***]</TD></TR> 
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">More than CHF [***] Net Sales and up to CHF [***] Net Sales</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom">[***]</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">More than CHF [***] Net Sales and up to CHF [***] Net Sales</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom">[***]</TD></TR> 
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">More than CHF [***] Net Sales</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom">[***]</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Products Generated during [***], Roche shall pay royalties to Pieris by applying [***] of the applicable royalty rate
specified in this Section. For Products Generated later than [***] Phase-out Term, no royalty payments shall be paid. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.6.3 Royalty
Reductions </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purpose of calculating royalties of a Product, Calendar Year Net Sales and the royalty rates shall be subject to the following
adjustments, as applicable: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.6.3.1 No Valid Claim </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If no Composition of Matter Claim of a patent owned or Controlled by Roche exists in a given country Covering the use, import, offering for sale, or sale of
the Product, or if such claim that previously existed loses its validity during the applicable Calendar Year, then the royalty payments due to Pieris for such Product in such country shall be reduced by [***]. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.6.3.2 Biosimilar Product </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the first
entry in a given country of a Biosimilar Product, the royalties in such country for such Product shall be reduced as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD> 
<TD ALIGN="left" VALIGN="top">If in any Calendar Quarter after entry of a Biosimilar Product there has been a decline of the Net Sales of the applicable Product in such country greater than [***] of the level of the Net Sales of such Product
achieved in the two consecutive Calendar Quarters immediately prior to such entry, then the royalty payments due to Pieris for such Product in such country shall be reduced by [***] for the remainder of the Royalty Term as from such Calendar
Quarter. </TD></TR></TABLE> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 29 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD> 
<TD ALIGN="left" VALIGN="top">If in any Calendar Quarter after entry of a Biosimilar Product there has been a decline of the Net Sales of the applicable Product in such country greater than [***] of the level of the Net Sales of such Product
achieved in the two consecutive Calendar Quarters immediately prior to such entry, then the royalty payments due to Pieris for such Product in such country shall end as from such Calendar Quarter and no royalties shall be due by Roche in such
country for such Product, and the license in that country for such Product shall be fully paid-up and irrevocable. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.6.4
Products used as Diagnostics </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding anything contained in this Section&nbsp;10.6, no royalty payments shall be paid to Pieris in the event that a
Product is itself developed, used and commercialized as a Companion Diagnostic Product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In case a Product is developed, used and commercialized as a
Stand-alone Diagnostic Product, the Parties shall agree on royalties to be paid on Net Sales of such Product in good faith, but in any case lower than those specified in this Section. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.7 Combination Product </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If Roche or its Affiliates
intend to sell a Combination Product, then the Parties shall meet approximately [***] prior to the anticipated First Commercial Sale of such Combination Product in the Territory to negotiate in good faith and agree to an appropriate adjustment to
Net Sales to reflect the relative commercial value contributed by the components of the Combination Product (the &#147;<B>Relative Commercial Value</B>&#148;). If, after such good faith negotiations not to exceed [***], the Parties cannot agree to
an appropriate adjustment, the dispute shall be initially referred to the executive officers of the Parties in accordance with Section&nbsp;21.2. Should the Parties fail to agree [***] of such referral, then the Relative Commercial Value shall be
determined by an Expert Committee under the procedures of this Section. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Parties are unable to agree on the Relative Commercial Value, then Roche
will select one (1)&nbsp;individual who would qualify as an Expert, Pieris will select (1)&nbsp;individual who would qualify as an Expert, and those two (2)&nbsp;individuals shall select one (1)&nbsp;individual who would qualify as an Expert and who
shall be chairman of a committee of the three Experts (the &#147;<B>Expert Committee</B>&#148;), each with a single deciding vote. The Expert Committee will promptly hold a meeting to review the issue under review, at which it will consider
memoranda submitted by each Party at least [***] before the meeting, as well as reasonable presentations that each Party may present at the meeting. The determination of the Expert Committee as to the issue under review will be binding on both
Parties. The Parties will share equally in the costs of the Expert Committee. Unless otherwise agreed to by the Parties, the Expert Committee may not decide on issues outside the scope mandated under terms of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, for any Combination Product that includes a Companion Diagnostic Product (i.e., not a Companion Diagnostic), the Relative
Commercial Value of such Companion Diagnostic Product shall be [***] </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.8 Third Party Payments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With the exception of Pieris IP, Roche shall be responsible for and pay or have paid any consideration owed to any Third Party in relation to Third Party
intellectual property rights. Roche shall have the right to deduct a maximum of </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="4%">&nbsp;</TD> 
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD> 
<TD ALIGN="left" VALIGN="top">[***], if such Third Party intellectual property rights Cover the [***] in such Product; or </TD></TR></TABLE> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 30 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="4%">&nbsp;</TD> 
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD> 
<TD ALIGN="left" VALIGN="top">[***] if such Third Party intellectual property rights Cover any other part of the Product, provided, however, that no such [***] reduction shall apply if (i)&nbsp;such Third Party intellectual property rights Cover a
molecule targeting an antigen other than the Target and such molecule is part of a Combination Product whose sales have been deducted from Net Sales per Section&nbsp;10.7, or (ii)&nbsp;such Third Party intellectual property rights Cover Roche
Technology existing as of the Effective Date and used in the Product; </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">of such consideration actually paid to a Third Party from any
payments otherwise due and payable by Roche to Pieris under this Agreement. Any such deduction shall be permitted on a Product-by-Product and country-by-country basis. In no event shall the amount of royalties payable to Pieris for a given Calendar
Year be reduced to lower than [***] of the royalties otherwise due for the Net Sales of such Product for the applicable Calendar Year as a result of deductions made under this Section. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10.9 Disclosure of Payments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each Party acknowledges that
the other Party may be obligated to disclose this financial arrangement, including all fees, payments and transfers of value, as may be advisable or required under Applicable Law, including the US Sunshine Act. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Accounting and reporting </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.1 Timing of Payments
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Roche shall calculate royalty payments set forth in Section&nbsp;10.6 quarterly as of March&nbsp;31,&nbsp;June&nbsp;30,&nbsp;September&nbsp;30 and
December&nbsp;31 (each being the last day of a reporting period). Roche shall pay such payments quarterly within [***] after the end of each reporting period in which Net Sales occur. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.2 Late Payment </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any payment under this Agreement that
is not paid on or before the date such payment is due shall bear interest, to the extent permitted by Applicable Law, at [***] above the average one-month Euro Interbank Offered Rate (EURIBOR), as reported by Reuters from time to time, calculated on
the number of days such payment is overdue. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.3 Method of Payment </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Royalties on Net Sales and all other amounts payable by Roche hereunder shall be paid by Roche in Swiss francs (the &#147;<B>Payment Currency</B>&#148;) to
account(s) designated by Pieris, except Research Costs according to Section&nbsp;10.2 which shall be paid to such account(s) in Euros. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.4 Currency
Conversion </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When calculating the Sales of any royalty-bearing Product that occur in currencies other than the Payment Currency, Roche shall convert the
amount of such sales into the Payment Currency using Roche&#146;s then-current internal foreign currency translation actually used on a consistent basis in preparing its audited financial statements (at the Effective Date, YTD average rate as
reported by Reuters). </P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 31 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11.5 Reporting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With each payment Roche shall provide Pieris in writing for the relevant Calendar Quarter on a Product-by-Product and [***] (i.e. [***]) basis the following
information: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="4%">&nbsp;</TD> 
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD> 
<TD ALIGN="left" VALIGN="top">Sales in the Payment Currency; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="4%">&nbsp;</TD> 
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD> 
<TD ALIGN="left" VALIGN="top">Net Sales in the Payment Currency; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="4%">&nbsp;</TD> 
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c)</TD> 
<TD ALIGN="left" VALIGN="top">adjustments made pursuant to Section 10.7<I>;</I> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="4%">&nbsp;</TD> 
<TD WIDTH="4%" VALIGN="top" ALIGN="left">d)</TD> 
<TD ALIGN="left" VALIGN="top">Net Sales in the Payment Currency after adjustments made pursuant to Section&nbsp;10.7 in the Payment Currency; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="4%">&nbsp;</TD> 
<TD WIDTH="4%" VALIGN="top" ALIGN="left">e)</TD> 
<TD ALIGN="left" VALIGN="top">royalty rate pursuant to Section&nbsp;10.6.2; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="4%">&nbsp;</TD> 
<TD WIDTH="4%" VALIGN="top" ALIGN="left">f)</TD> 
<TD ALIGN="left" VALIGN="top">adjustments made pursuant to Sections 10.6.3 and 10.8; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="4%">&nbsp;</TD> 
<TD WIDTH="4%" VALIGN="top" ALIGN="left">g)</TD> 
<TD ALIGN="left" VALIGN="top">total royalty payable in the Payment Currency. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. Taxes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pieris shall pay all sales, turnover, income, revenue, value added, and other taxes levied on account of any payments accruing or made to Pieris under this
Agreement. Roche agrees to reasonably assist Pieris in claiming exemption from such taxes and in minimizing the amount required to be so paid. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If
provision is made in law or regulation of any country for withholding of taxes of any type, levies or other charges with respect to any royalty or other amounts payable under this Agreement to Pieris, then Roche shall promptly pay such tax, levy or
charge for and on behalf of Pieris to the proper governmental authority, and shall promptly furnish Pieris with receipt of payment. Roche shall be entitled to deduct any such tax, levy or charge actually paid from royalty or other payment due to
Pieris or be promptly reimbursed by Pieris if no further payments are due to Pieris. Each Party agrees to reasonably assist the other Party in claiming exemption from such deductions or withholdings under double taxation or similar agreement or
treaty from time to time in force and in minimizing the amount required to be so withheld or deducted. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. Auditing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13.1 Pieris&#146; Right to Audit </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Roche shall keep, and
shall require its Affiliates and Sublicensees to keep, full, true and accurate books of account containing all particulars that may be necessary for the purpose of calculating all royalties payable under this Agreement. Such books of accounts shall
be kept at their principal place of business. At the expense of Pieris, Pieris shall have the right to engage an independent public accountant reasonably acceptable to Roche to perform, on behalf of Pieris an audit of such books and records of Roche
and its Affiliates, its licensees and Sublicensees, that are deemed necessary by Roche&#146;s independent public accountant to report on Net Sales of Product for the period or periods requested by Pieris, and the correctness of any financial report
or payments made under this Agreement. </P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 32 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon timely request and at least [***] prior written notice from Pieris, such audit shall be conducted in the
countries specifically requested by such independent public accountant, during regular business hours in such a manner as to not unnecessarily interfere with Roche&#146;s normal business activities, and shall be limited to results in the [***] prior
to audit notification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Such audit shall not be performed more frequently than [***] nor more frequently than once with respect to records covering any
specific period of time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All information, data documents and abstracts herein referred to shall be used only for the purpose of verifying royalty
statements, shall be treated as Roche&#146;s Confidential Information subject to the obligations of this Agreement and need neither be retained more than [***] after completion of an audit hereof, if an audit has been requested; nor more than [***]
from the end of the Calendar Year to which each shall pertain; nor more than [***] after the date of termination of this Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13.2 Audit Reports
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The auditors shall only state factual findings in the audit reports and shall not interpret the agreement. The auditors shall share all draft audit
reports with Roche before the draft report is shared with Pieris and before the final document is issued. The final audit report shall be shared with Roche at the same time it is shared with Pieris. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13.3 Over- or Underpayment </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the audit reveals an
overpayment, Pieris shall reimburse Roche for the amount of the overpayment within [***]. If the audit reveals an underpayment, Roche shall make up such underpayment with the next royalty payment or, if no further royalty payments are owed by Roche,
Roche shall reimburse Pieris for the amount of the underpayment within [***]. Roche shall pay for the audit costs if the underpayment of Roche exceeds [***] of the aggregate amount of royalty payments owed with regard to the royalty statements
subject to the audit. Section&nbsp;11.2 shall apply to this Section&nbsp;13.3. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13.4 Duration of Audit Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The failure of Pieris to request verification of any royalty calculation within the period during which corresponding records must be maintained under this
Article 13 will be deemed to be acceptance of the royalty payments and reports. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.1 Ownership of Pieris IP and Roche IP </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pieris shall
remain the owner of Pieris IP, and Roche of Roche IP. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.2 Ownership of Inventions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pieris and Roche shall own Pieris Inventions and Roche Inventions, respectively. Joint Inventions shall be jointly owned by the Parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, Pieris shall own Inventions and Know-How solely related to improvements to the Pieris Technology, and Roche shall own
Inventions and Know-How solely related to improvements to the Roche Technology. Each Party shall, to the extent legally permitted, require all of its employees to assign all Inventions related to such improvements made by them. </P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 33 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pieris shall own any Inventions and Know-How related to [***]. Roche shall, to the extent legally permitted,
require all of its employees to assign all Inventions related to [***] made by them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding anything to the contrary in this Section&nbsp;14,
Roche shall own any Inventions and Know-How related to [***]. Pieris shall require all of its employees to assign all Inventions related to [***] made by them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as specifically set forth herein, this Agreement shall not be construed as (i)&nbsp;giving any of the Parties any license, right, title, interest in or
ownership to the Confidential Information; (ii)&nbsp;granting any license or right under any intellectual property rights; or (iii)&nbsp;representing any commitment by either Party to enter into any additional agreement, by implication or otherwise.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.3 German Statute on Employee&#146;s Inventions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with the German Statute on Employees&#146; Inventions, each Party agrees to claim the unlimited use of any Invention conceived, reduced to
practice, developed, made or created in the performance of, or as a result of, any research program by employees of any German Affiliates or any other persons acting on behalf of such German Affiliates. For the avoidance of doubt, each Party is
responsible for fulfilling the obligations towards their employees under the German Statute of Employee&#146;s Inventions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.4 Prosecution of Patent
Rights by Pieris </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pieris shall have the right to Handle its Patent Rights on Inventions assigned to Pieris pursuant to Section&nbsp;14.2 at its own
expense and with Roche&#146;s prior written consent (such consent not to be unreasonably withheld with regard to improvements to Pieris Technology) to the time point of filing any Patent Rights on such Inventions. When Handling its Patent Rights on
Inventions made under this Agreement, Pieris shall, at its own expense, (i)&nbsp;consult with Roche as to the Handling of such Patent Rights, and (ii)&nbsp;furnish to Roche copies of all documents relevant to any such Handling. Pieris shall furnish
such documents and consult with Roche in sufficient time before any action by Pieris is due to allow Roche to provide comments thereon, which comments Pieris must consider. At Pieris&#146; expense and reasonable request, Roche shall cooperate, in
all reasonable ways with the Handling of all of Pieris&#146; Patent Rights relating to Inventions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.5 Prosecution of Patent Rights by Roche </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Roche shall, at its own expense and discretion, Handle (including abandon) all its Patent Rights, including all Patent Rights claiming any [***], provided,
however, that prior to abandoning of any Valid Claims of any Patent Rights related to [***], Roche shall provide reasonable advanced written notice to Pieris before abandoning such Patent Rights, in which case Pieris shall have the right to assume,
at Pieris&#146; cost, ownership of such Patent Rights as well as the right to continue maintenance thereof. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.6 CREATE Act </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is the intention of the Parties that this Agreement is a &#147;joint research agreement&#148; as that phrase is defined in 35 USC &#167;103(c)(3). </P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 34 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.7 Defense </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the manufacture, use, importation, offer for sale or sale of any Product pursuant to this Agreement results in any claim, suit or proceeding alleging patent
infringement or trade secret misappropriation against Pieris or a member of the Roche Group, then such Party shall promptly notify the other Party hereto. The Parties shall cooperate with each other in connection with any such claim, suit or
proceeding and shall keep each other reasonably informed of all material developments in connection with any such claim, suit or proceeding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a Third
Party asserts that Patent Rights owned by or licensed to it are infringed by the development, manufacture, use, importation, offer for sale or sale of Products by a member of the Roche Group, or that its trade secrets were misappropriated in
connection with such activity, then Roche shall have the exclusive right and responsibility to resolve any such claim, whether by obtaining a license from such Third Party, by defending against such Third Party&#146;s claims or otherwise, and shall
be solely responsible for the defense of any such action, any and all costs incurred in connection with such action (including, without limitation, attorneys&#146; and expert fees) and all liabilities incurred in connection therewith.
Notwithstanding the above, Roche shall not enter into any settlement of any such claim without the prior written consent of Pieris if such settlement would require Pieris to be subject to an injunction or to make any monetary payment to Roche or any
Third Party, or admit any wrongful conduct by Pieris or its Affiliates, or would limit or restrict the claims of or admit any invalidity and/or unenforceability of any of the Patent Rights Controlled by Pieris, or have any impact on activities
outside the Field. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an action for infringement is commenced against Pieris, its licensees or its sublicensees related to Pieris&#146;s conduct of the
research program within the scope of the Research Plan or the discovery of a Product, then Pieris shall have the right (but not the obligation) to defend such action at its own expense, and Roche shall assist and cooperate with Pieris, at
Pieris&#146; expense, to the extent necessary in the defense of such suit. Pieris shall have the right to settle the suit or consent to an adverse judgment thereto, in its sole discretion, so long as such settlement or adverse judgment does not
adversely affect the rights of Roche and its Affiliates (including any patent rights Controlled by any of them). Pieris shall assume full responsibility for the payment of any award for damages, or any amount due pursuant to any settlement entered
into by it with such Third Party. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.8 Enforcement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.8.1 Enforcement of Patent Rights relating to [***] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Roche shall have the full and unrestricted right, but not the obligation, to bring and control an appropriate suit or other action against any person or entity
engaged in any infringement action or proceeding to the extent directly relating to Patent Rights relating to [***], in its own name and entirely under its own direction and control. If Roche requests so, Pieris shall reasonably cooperate with Roche
in the planning and execution of any such action to enforce such Patent Rights (including the obligation to be named or joined as a party in a lawsuit, as applicable). All monies recovered upon the final judgment or settlement of any such suit or
action to enforce such Patent Rights subtracting any costs that Roche bore in connection with such suit or action shall be calculated as Net Sales. In the event that Roche does not wish to enforce such Patent Rights against such a potential
infringer, then Roche shall deliver prompt written notice thereof to Pieris. </P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 35 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.8.2 Enforcement of Patent Rights related to Pieris IP </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pieris shall have the first right, but not the obligation, to bring an appropriate suit or other action against any person or entity engaged in any
infringement action or proceeding to the extent directly relating to Pieris IP and to Patents relating to [***] (but excluding Patents relating to [***]). If Pieris fails to commence a suit to enforce the applicable Pieris IP and to Patents relating
to [***] or to settle or otherwise secure the abatement of such action or proceeding within a reasonable period, then Roche shall have the right, but not the obligation, to commence a suit or take action to enforce such Patent Rights against such
infringement action or proceeding in the Field in the Territory at its own cost and expense, and only to the extent such action or proceeding is related to the Product(s). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.9 Common Interest Disclosures </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With regard to any
information or opinions disclosed pursuant to this Agreement by one Party to each other regarding intellectual property and/or technology owned by Third Parties, the Parties agree that they have a common legal interest in determining whether, and to
what extent, Third Party intellectual property rights may affect the conduct of the Research Plan and/or Compounds and/or Products, and have a further common legal interest in defending against any actual or prospective Third Party claims based on
allegations of misuse or infringement of intellectual property rights relating to the conduct of the Research Plan and/or Compounds and/or Products. Accordingly, the Parties agree that all such information and materials obtained by Pieris and Roche
from each other will be used solely for purposes of the Parties&#146; common legal interests with respect to the conduct of the Agreement. All information and materials will be treated as protected by the attorney-client privilege, the work product
privilege, and any other privilege or immunity that may otherwise be applicable. By sharing any such information and materials, neither Party intends to waive or limit any privilege or immunity that may apply to the shared information and materials.
Neither Party shall have the authority to waive any privilege or immunity on behalf of the other Party without such other Party&#146;s prior written consent, nor shall the waiver of privilege or immunity resulting from the conduct of one Party be
deemed to apply against any other Party. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.10 Biosimilar or interchangeable biological products </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If Roche requests so, within four (4)&nbsp;years after the approval of a Product that has been licensed in the US as a biological product under 42 USC
&#167;262(a), and as may be needed from time to time thereafter, the Parties shall consult as to potential strategies with respect to unexpired US Patent Rights that Cover the Product. Specifically, in anticipation of a receipt by the Product&#146;s
reference product sponsor (&#147;<B>Reference Product Sponsor</B>&#148;) of a biosimilar or interchangeable product application pursuant to the Biologics Price Competition and Innovation Act of 2009 (Public Law 111-148), the Parties will discuss the
Reference Product Sponsor&#146;s likely course of action with regard to each such US Patent Right in the procedural steps set forth under 42 USC &#167;262(l), including a general plan for timely communication between the Parties in light of the
statutory response deadlines. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14.11 Patent Term Extensions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Parties shall use Commercially Reasonable Efforts to obtain all available patent term extensions, adjustments or restorations, or supplementary protection
certificates (&#147;<B>SPCs</B>&#148;, and together with patent term extensions, adjustments and restorations, &#147;<B>Patent Term Extensions</B>&#148;). Pieris shall execute such authorizations and other documents and take such other actions as
may be reasonably requested by Roche to obtain such Patent Term Extensions, including designating Roche as its agent for such purpose as provided in 35 U.S.C. Section&nbsp;156. All filings for such Patent Term Extensions shall be made by Roche;
provided, that in the event that Roche elects not to file for a Patent Term Extension, Roche shall (a)&nbsp;promptly inform Pieris of its </P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 36 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
intention not to file and (b)&nbsp;grant Pieris the right to file for such Patent Term Extension. Each Party shall execute such authorizations and other documents and take such other actions as
may be reasonably requested by the other Party to obtain such extensions. The Parties shall cooperate with each other in gaining patent term restorations, extensions and/or SPCs wherever applicable to such Patent Rights. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. Representations and Warranties </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15.1 Third Party
Patent Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the Effective Date, Pieris has no knowledge of the existence of any patent or patent application owned by or licensed to any Third
Party that could prevent Roche from making, having made, using, offering for sale, selling or importing [***] in the Territory. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15.2 Ownership of
Patent Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pieris is the exclusive owner of all right, title and interest in, or is the exclusive licensee, with the right to sublicense in the
Field and in the Territory of, the Patent Rights related to Pieris IP. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15.3 Inventors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pieris warrants that, for Patent Rights owned by Pieris and its Affiliates, the inventors of the Inventions disclosed and/or claimed in Pieris IP have
transferred to Pieris full ownership of the patent rights and know-how licensed under this Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15.4 Grants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the best of Pieris&#146; knowledge and belief, Pieris has the lawful right to grant Roche and its Affiliates the rights and licenses described in this
Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15.5 Authorization </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The execution,
delivery and performance of this Agreement by either Party and all instruments and documents to be delivered by a Party hereunder: (i)&nbsp;are within the corporate power of such Party; (ii)&nbsp;have been duly authorized by all necessary or proper
corporate action; (iii)&nbsp;are not in contravention of any provision of the certificate of formation or limited liability company agreement of such Party; (iv)&nbsp;to the knowledge of such Party, will not violate any law or regulation or any
order or decree of any court of governmental instrumentality; (v)&nbsp;will not violate the terms of any indenture, mortgage, deed of trust, lease, agreement, or other instrument to which such Party is a party or by which such Party or any of its
property is bound, which violation would have an adverse effect on the financial condition of such Party or on the ability of such Party to perform its obligations hereunder; and (vi)&nbsp;do not require any filing or registration with, or the
consent or approval of, any governmental body, agency, authority or any other person, which has not been made or obtained previously (other than approvals required under the HSR Act, Regulatory Approvals required for the sale of Products and filings
with Regulatory Authorities required in connection with Products). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15.6 Validity of Patent Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the Effective Date, Pieris is not in possession of information that could render invalid and/or unenforceable any claims that are in any of the Patent
Rights related to Pieris IP. Pieris has no knowledge of any inventorship disputes concerning any Patent Rights related to Pieris IP. </P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 37 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15.7 Ownership and Validity of Know-How </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Know-How of each Party is legitimately in the possession of such Party and has not been misappropriated from any Third Party. The Parties have taken
reasonable measures to protect the confidentiality of its Know-How. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15.8 No Claims </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no claims or investigations, pending or threatened against Pieris or any of its Affiliates, at law or in equity, or before or by any governmental
authority relating to the matters contemplated under this Agreement and that would materially adversely affect Pieris&#146; ability to perform its obligations hereunder. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15.9 No Conflict </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither Party nor any of their
respective Affiliates is or will be under any obligation to any person, contractual or otherwise, that is conflicting with the terms of this Agreement or that would impede the fulfillment of their respective obligations hereunder. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15.10 No Other Representations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EXCEPT AS OTHERWISE
PROVIDED IN THIS AGREEMENT, THE FOREGOING REPRESENTATIONS AND WARRANTIES ARE IN LIEU OF ALL OTHER REPRESENTATIONS AND WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF
PRODUCTS, VALIDITY AND ENFORCEABILITY OF ANY PATENT RIGHT LICENSED HEREUNDER, AND NON-INFRINGEMENT OF ANY PRODUCT. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16. Indemnification </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16.1 Indemnification by Roche </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Roche shall indemnify, hold
harmless and defend Pieris and its directors, officers, employees and agents from and against any and all losses, expenses, cost of defense (including without limitation attorneys&#146; fees, witness fees, damages, judgments, fines and amounts paid
in settlement) and any amounts Pieris becomes legally obligated to pay because of any claim or claims against it to the extent that such claim or claims arise out of activities conducted by or on behalf of Roche under this Agreement, except to the
extent such losses, expenses, costs and amounts are due to the gross negligence or willful misconduct or failure to act of Pieris. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16.2
Indemnification by Pieris </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pieris shall indemnify, hold harmless and defend Roche and its directors, officers, employees and agents from and against
any and all losses, expenses, cost of defense (including without limitation attorneys&#146; fees, witness fees, damages, judgments, fines and amounts paid in settlement) and any amounts Roche becomes legally obligated to pay because of any claim or
claims against it to the extent that such claim or claims arise out of activities conducted by or on behalf of Pieris under this Agreement, except to the extent such losses, expenses, costs and amounts are due to the gross negligence or willful
misconduct or failure to act of Roche. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>16.3 Procedure </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of a claim by a Third Party against a Party entitled to indemnification under this Agreement (&#147;<B>Indemnified Party</B>&#148;), the
Indemnified Party shall promptly notify the other Party (&#147;<B>Indemnifying Party</B>&#148;) in writing of the claim and the Indemnifying Party shall undertake and </P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 38 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
solely manage and control, at its sole expense, the defense of the claim and its settlement. The Indemnified Party shall cooperate with the Indemnifying Party and may, at its option and expense,
be represented in any such action or proceeding by counsel of its choice. The Indemnifying Party shall not be liable for any litigation costs or expenses incurred by the Indemnified Party without the Indemnifying Party&#146;s written consent. The
Indemnifying Party shall not settle any such claim unless such settlement fully and unconditionally releases the Indemnified Party from all liability relating thereto, unless the Indemnified Party otherwise agrees in writing. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17. Liability </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17.1 Limitation of Liability </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to Section&nbsp;4.2, neither Party shall be liable to the other Party as a result of failure or delay to develop and/or commercialize the Product(s),
as applicable, including but not limited to, a) a delay in timelines, or b) delay or failure to recruit patients, or c) a change in its respective study protocols, or d) failure of the other Party to obtain regulatory approval for the Product(s), as
applicable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>17.2 Disclaimer </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THE FOREGOING
REPRESENTATIONS AND WARRANTIES ARE IN LIEU OF ALL OTHER REPRESENTATIONS AND WARRANTIES NOT EXPRESSLY SET FORTH HEREIN. PIERIS AND ROCHE DISCLAIM ALL OTHER WARRANTIES, WHETHER EXPRESS OR IMPLIED, WITH RESPECT TO EACH OF THEIR RESEARCH, DEVELOPMENT
AND COMMERCIALIZATION EFFORTS HEREUNDER, INCLUDING, WITHOUT LIMITATION, WHETHER THE PRODUCTS CAN BE SUCCESSFULLY DEVELOPED OR MARKETED, THE ACCURACY, PERFORMANCE, UTILITY, RELIABILITY, TECHNOLOGICAL OR COMMERCIAL VALUE, COMPREHENSIVENESS,
MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE WHATSOEVER OF THE PRODUCTS. IN NO EVENT SHALL EITHER PIERIS OR ROCHE BE LIABLE FOR SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES ARISING OUT OF THIS AGREEMENT BASED ON CONTRACT, TORT OR
ANY OTHER LEGAL THEORY. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18. Obligation Not to Disclose Confidential Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18.1 Non-Use and Non-Disclosure </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the Agreement Term
and for [***] thereafter, a Receiving Party shall (i)&nbsp;treat Confidential Information provided by Disclosing Party as it would treat its own information of a similar nature, (ii)&nbsp;take all reasonable precautions not to disclose such
Confidential Information to Third Parties, without the Disclosing Party&#146;s prior written consent, and (iii)&nbsp;not use such Confidential Information other than for fulfilling its obligations under this Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18.2 Permitted Disclosure </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the obligation
of non-use and non-disclosure set forth in Section&nbsp;18.1, the Parties recognize the need for certain exceptions to this obligation, specifically set forth below, with respect to press releases, patent rights, publications, and certain commercial
considerations. </P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 39 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18.3 Press Releases </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Parties may issue a press release announcing the existence and selected key terms of this Agreement, as attached as Appendix 18.3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Roche shall issue press releases in accordance with its internal policy that typically does not issue a second press release until proof of concept has been
achieved for a Product. Roche shall provide Pieris with a copy of any draft press release related to the Agreement at least [***] prior to its intended publication for Pieris&#146; review. Pieris may provide Roche with suggested modification to the
draft press release. Roche shall consider Pieris&#146; timely suggestions in issuing its press release. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pieris shall only issue press releases related to
the activities contemplated by this Agreement that have either (i)&nbsp;been approved by Roche (such approval not to be unreasonably withheld), or (ii)&nbsp;are required to be issued by Pieris as a matter of law and Pieris has a competent legal
opinion to that effect. In all circumstances, Pieris shall provide Roche with a draft press release at least [***] prior to its intended publication for Roche&#146;s review. During such period, Roche shall (i)&nbsp;approve the draft press release
and permit Pieris to issue the press release, (ii)&nbsp;contact Pieris to discuss modification to the draft press release, or (iii)&nbsp;contact Pieris and disapprove the press release. If Roche asks for modification, then Pieris shall either make
such modification or work with Roche to arrive at a press release that Roche approves. If Pieris issues a press release without Roche&#146;s approval, then Pieris must obtain a competent legal opinion that the release was required to be issued by
Pieris as a matter of law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18.4 Publications </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During
the Agreement Term, the following restrictions shall apply with respect to disclosure by any Party of Confidential Information relating to the Product in any publication or presentation: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD> 
<TD ALIGN="left" VALIGN="top">Both Parties acknowledge that it is their policy for the studies and results thereof to be registered and published in accordance with their internal guidelines. Roche, in accordance with its internal policies and
procedures, shall have the right to publish all studies, clinical trials and results thereof on the clinical trial registries that are maintained by or on behalf of Roche. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD> 
<TD ALIGN="left" VALIGN="top">A Party (&#147;<B>Publishing Party</B>&#148;) shall provide the other Party with a copy of any proposed publication or presentation at least [***] prior to submission for publication so as to provide such other Party
with an opportunity to recommend any changes it reasonably believes are necessary to continue to maintain the Confidential Information disclosed by the other Party to the Publishing Party in accordance with the requirements of this Agreement. The
incorporation of such recommended changes shall not be unreasonably refused; and if such other Party notifies (&#147;<B>Publishing Notice</B>&#148;) the Publishing Party in writing, within [***] after receipt of the copy of the proposed publication
or presentation, that such publication or presentation in its reasonable judgment (i)&nbsp;contains an invention, solely or jointly conceived and/or reduced to practice by the other Party, for which the other Party reasonably desires to obtain
patent protection or (ii)&nbsp;could be expected to have a material adverse effect on the commercial value of any Confidential Information disclosed by the other Party to the Publishing Party, the Publishing Party shall prevent such publication or
delay such publication for a mutually agreeable period of time. In the case of inventions, a delay shall be for a period reasonably sufficient to permit the timely preparation and filing of a patent application(s) on such invention, and in no event
less than [***] from the date of the Publishing Notice. </TD></TR></TABLE> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 40 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>18.5 Commercial Considerations </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="4%">&nbsp;</TD> 
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD> 
<TD ALIGN="left" VALIGN="top">Nothing in this Agreement shall prevent Roche or its Affiliates from disclosing Confidential Information of Pieris to (i)&nbsp;governmental agencies to the extent required or desirable to secure government approval for
the development, manufacture or sale of Product(s) in the Territory, (ii)&nbsp;Third Parties acting on behalf of Roche, to the extent reasonably necessary for the development, manufacture or sale of Product(s) in the Territory, or (iii)&nbsp;Third
Parties to the extent reasonably necessary to market the Product in the Territory, provided that for disclosures according to (ii)&nbsp;or (iii)&nbsp;of this Section, such Third Parties will be subject to the same confidentiality obligations as
Roche has hereunder. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="4%">&nbsp;</TD> 
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD> 
<TD ALIGN="left" VALIGN="top">Nothing in this Agreement shall prevent Pieris or its Affiliates from disclosing (1)&nbsp;Confidential Information of Roche to (i)&nbsp;governmental agencies to the extent required or desirable to secure government
approval for the development, manufacture or sale of Product(s) in the Territory as provided for in Section&nbsp;19.3.4, (ii)&nbsp;Third Parties acting on behalf of Pieris, to the extent reasonably necessary for (A)&nbsp;Pieris to perform its
activities and obligations under the Research Plan, or (B)&nbsp;the development, manufacture or sale of Product(s) in the Territory as provided for in Section&nbsp;19.3.4, or (iii)&nbsp;Third Parties to the extent reasonably necessary to market the
Product in the Territory as provided for in Section&nbsp;19.3.4, or (2)&nbsp;to a Third Party the terms of this Agreement as part of confidential due diligence carried out by such Third Party in connection with a potential Change of Control of
Pieris; provided that for disclosures according to (1)&nbsp;(ii)&nbsp;and (iii)&nbsp;or (2)&nbsp;of this Section, such Third Parties will be subject to the same confidentiality obligations as Pieris has hereunder. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="4%">&nbsp;</TD> 
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD> 
<TD ALIGN="left" VALIGN="top">The Receiving Party may disclose Confidential Information of the Disclosing Party to the extent that such Confidential Information is required to be disclosed by the Receiving Party to comply with Applicable Law, to
defend or prosecute litigation or to comply with governmental regulations, provided that the Receiving Party provides prior written notice of such disclosure to the Disclosing Party and, to the extent practicable, takes reasonable and lawful actions
to minimize the degree of such disclosure. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>19. Term and Termination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>19.1 Commencement and Term </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Agreement shall commence
upon the Effective Date and continue for the Agreement Term. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>19.2 Termination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19.2.1 Termination for Breach </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Party
(&#147;<B>Non-Breaching Party</B>&#148;) shall have the right to terminate this Agreement in its entirety or on a country-by-country basis in the event the other Party (&#147;<B>Breaching Party</B>&#148;) is in breach of any of its material
obligations under this Agreement. The Non-Breaching Party shall provide written notice to the Breaching Party, which notice shall identify the breach and the countries in which the Non-Breaching Party intends to have this Agreement terminate. The
Breaching Party shall have a period of ninety (90) days after such written notice is provided (&#147;<B>Peremptory Notice Period</B>&#148;) to cure such breach. If the Breaching Party has a dispute as to whether such breach occurred or has been
cured, it will so notify the Non-Breaching Party, and the expiration of the Peremptory Notice Period shall be tolled until such dispute is resolved pursuant to Section&nbsp;21.2. Upon a determination of breach or failure to cure, the Breaching Party
may have the remainder of the Peremptory Notice Period to cure such breach. If such breach is not cured within the Peremptory Notice Period, then absent withdrawal of the Non-Breaching Party&#146;s request for termination, this Agreement shall
terminate in such countries effective as of the expiration of the Peremptory Notice Period. </P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 41 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19.2.2 Insolvency </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Party shall have the right to terminate this Agreement, if the other Party incurs an Insolvency Event; provided, however, in the case of any involuntary
bankruptcy proceeding, such right to terminate shall only become effective if the Party that incurs the Insolvency Event consents to the involuntary bankruptcy or such proceeding is not dismissed within [***] after the filing thereof. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19.2.3 Effects of Change of Control </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If there is
a Change of Control, then the Party experiencing such Change of Control (&#147;<B>Acquired Party</B>&#148;) shall provide written notice to the other Party (&#147;<B>Non-Acquired Party</B>&#148;) at least [***] to completion of such Change of
Control, subject to any confidentiality obligations of the Acquired Party then in effect (but in any event shall notify the Non-Acquired Party within [***] after completion of such Change of Control). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Change of Control Group in connection with such Change of Control shall agree in writing with the Non-Acquired Party that it will not utilize any of the
Non-Acquired Party&#146;s Know-How, Patent Rights, Inventions, or Confidential Information (collectively, &#147;<B>Sensitive Information</B>&#148;) for the research, development or commercialization of any product for the treatment of any indication
or patient population for which a Product may be developed or commercialized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following consummation of the Change of Control, the Non-Acquired Party and
the Change of Control Group shall adopt in writing reasonable procedures to prevent the disclosure of Sensitive Information beyond the Acquired Party&#146;s personnel who need to know the Sensitive Information solely for the purpose of fulfilling
the Acquired Party&#146;s obligations under this Agreement. The Non-Acquired Party may restrict the Acquired Party&#146;s participation in the JRC and any other committee in effect at the time of the Change of Control, and decisions of the JRC and
other such committees shall be made by Roche. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If there is a Change of Control of Pieris involving a company that develops or commercializes
biopharmaceutical products (for clarity, generally for itself and not typically on a contract basis for other companies), then Roche may, in its sole discretion, immediately terminate the Agreement in its entirety. Upon any such termination by
Roche, Pieris will immediately cease all activity and transfer to Roche all data developed by Pieris. Pieris shall provide an invoice to Roche specifying the, and reconcile [***] made by Roche. Within [***] of such reconciliation, Pieris will refund
to Roche the difference between the [***] by Roche and Pieris actual FTE expenditures [***]. All licenses granted by Pieris to Roche shall remain in effect subject to the payment and diligence obligations under this Agreement. Pieris shall lose the
right to query Roche for the [***] as foreseen in Section&nbsp;2.4, and all licenses granted by Roche to Pieris shall terminate, except for the licenses under Section&nbsp;2.4 with regards to licenses for [***] already granted and for which Pieris
is [***] and provided that the Change of Control Group or its sublicensees develop such [***] without the use of any Sensitive Information. Further, the right to query Roche for the [***] and Roche&#146;s grant of licenses for such [***] as foreseen
under Section&nbsp;2.4 shall remain in effect provided that the Change of Control of Pieris involves a company as described above that, at the time of such Change of Control, (i)&nbsp;has a market capitalization of less than [***] US dollars (USD
[***]) and (ii)&nbsp;has [***]. </P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 42 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19.2.4 Voluntary Termination by Roche </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Termination Without a Cause </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After [***] from the
Effective Date, Roche shall have the right to terminate this Agreement at any time as a whole, or on a Product-by-Product and country-by-country basis upon [***] prior written notice before First Commercial Sale of a Product or upon [***] prior
written notice after the First Commercial Sale of a Product. For clarity, Roche shall have the right to provide written notice of termination before the end of the initial [***], but such termination shall only take effect when the initial [***]
have ended. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective Date of Termination </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The effective date of termination under this Section&nbsp;19.2.4 shall be the date [***] (or [***] as the case may be) after Roche provides such written notice
to Pieris. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>19.3 Consequences of Termination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19.3.1 Termination by Pieris for Breach by Roche </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon any termination by Pieris for breach by Roche, the rights and licenses granted by Pieris to Roche under this Agreement shall terminate in their entirety
or on a country-by-country and Product-by-Product basis, as applicable, on the effective date of termination, and all licenses granted by Roche to Pieris under Section&nbsp;2.4 shall remain in effect. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19.3.2 Termination by Roche for Breach by Pieris or Pieris&#146; Insolvency </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon any termination by Roche for breach by Pieris or Pieris&#146; Insolvency, Roche and its Affiliates may upon notice retain all rights and licenses granted
to Roche by Pieris under this Agreement; provided that after the effective date of termination the amounts of such payments and royalties that otherwise would have become due and payable shall continue to be due and payable to Pieris or its
successor in interest (as applicable). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19.3.3 Voluntary Termination by Roche </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon any voluntary termination by Roche, the rights and licenses granted by Pieris to Roche under this Agreement shall terminate in their entirety or on a
country-by-country and Product-by Product basis, as applicable, on the effective date of termination, and all licenses granted by Roche to Pieris under Section&nbsp;2.4 shall remain in effect. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19.3.4 Continuation Election Notice </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the case
of termination by Pieris for breach by Roche (Section 19.3.1) or in case of voluntary termination by Roche (Section 19.3.3), if Pieris desires to continue development and/or commercialization of Product(s), Pieris shall give a Continuation Election
Notice to Roche within [***] of receipt of Pieris&#146; or Roche&#146;s notice of termination, as applicable, and pay [***] Swiss francs (CHF [***]) within [***] after receipt of respective invoice from Roche. If Roche receives such a timely
Continuation Election Notice, and to the extent reasonably requested by Pieris: </P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 43 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="4%">&nbsp;</TD> 
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD> 
<TD ALIGN="left" VALIGN="top">At Roche&#146;s choice, Roche shall either grant to Pieris an exclusive (with respect to the terminated territory and Product only) and royalty free license to Patent Rights only to the extent covering Inventions
relating to [***] that Roche received from Pieris under Section&nbsp;14.2 and to the extent necessary to continue development and/or commercialization of the terminated Product in the terminated territory, or assign and transfer to Pieris such
Patent Rights, free of charge. For clarity, if such Patent Rights also cover Inventions relating to [***] or other subject matters, the license to such Inventions shall be subject to Section&nbsp;19.3.4 (b). </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="4%">&nbsp;</TD> 
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD> 
<TD ALIGN="left" VALIGN="top">The Parties shall enter into good faith negotiations with regards to a royalty-bearing license, with the right to grant sublicenses (through multiple tiers), under intellectual property and rights owned by Roche not
covered under Section&nbsp;19.3.4 (a)&nbsp;and relating to Products [***] (for clarity, [***] are excluded from such license). Such license shall be under terms to be negotiated in good faith between the Parties, taking into account the value of
such intellectual property and rights and the contribution made by Roche to the development of the Product(s) and their development stage. The good faith negotiations for a license described in this Section shall in particular address:
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="8%">&nbsp;</TD> 
<TD WIDTH="5%" VALIGN="top" ALIGN="left">i.</TD> 
<TD ALIGN="left" VALIGN="top">The obligation of Roche to, to the extent Roche has the right to do so, transfer to Pieris all material regulatory correspondence, filings (including all Filings) and approvals (including all Regulatory Approvals), all
final pre-clinical and clinical study reports and clinical study protocols, and all data, including clinical data, in Roche&#146;s possession or control related to Product(s) in the country useful or necessary for Pieris to continue to develop,
manufacture and commercialize the Product(s). All data shall be transferred in the form and format in which it is maintained by Roche. Original paper copies shall only be transferred, if legally required. Roche shall not be required to prepare or
finalize any new data, reports or information solely for purposes of transfer to Pieris. In connection with research studies or clinical trials, Roche may have collected human samples and related clinical information for additional limited research
and development programs (&#147;<B>Samples</B>&#148;). Legal and contractual restrictions may apply to such Samples, in particular as Samples may qualify as personal identifiable information. Roche shall transfer any such Samples to Pieris to the
extent permitted by the informed consents as originally established with respect to such Samples and Applicable Laws. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="8%">&nbsp;</TD> 
<TD WIDTH="5%" VALIGN="top" ALIGN="left">ii.</TD> 
<TD ALIGN="left" VALIGN="top">Assignment of all clinical trial agreements and any other Third Party agreement relating to the development, manufacture or commercialization of a Product, to the extent such agreements have not been cancelled and are
assignable without Roche paying any consideration or commencing litigation in order to effect an assignment of any such agreement (and the obligation of Roche to use Commercially Reasonable Efforts to obtain consent from the concerned Third Party to
such a transfer). </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="8%">&nbsp;</TD> 
<TD WIDTH="5%" VALIGN="top" ALIGN="left">iii.</TD> 
<TD ALIGN="left" VALIGN="top">The obligation of Pieris to [***] incurred by or on behalf of Roche for transfer activities from Roche to Pieris to the extent such costs and expenses exceed the fee of [***] Swiss francs (CHF [***]) paid by Pieris
under this Section. </TD></TR></TABLE> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 44 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="8%">&nbsp;</TD> 
<TD WIDTH="5%" VALIGN="top" ALIGN="left">iv.</TD> 
<TD ALIGN="left" VALIGN="top">The obligation of Pieris to pay royalties to Roche on Net Sales of such Product(s). Such royalties shall be dependent on the then-current development stage of the Product(s) according to the following table:
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

 
<TR> 
<TD WIDTH="86%"></TD> 
<TD VALIGN="bottom" WIDTH="9%"></TD> 
<TD></TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:8pt"> 
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:105.35pt; font-size:8pt; font-family:Times New Roman">Development stage of Product(s)</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Royalty&nbsp;rate</TD></TR>

 
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prior to start of Phase II Study</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">After start of Phase II Study but before Start of Phase III Study</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR> 
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">After Start of Phase III Study but before First Commercial Sale</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">After First Commercial Sale</P></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom" ALIGN="center">[***]</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">The above royalty rates shall be reduced by [***] on a Product-by-Product and country-by-country basis in each
country in which the manufacture, use, sale or import of the Product(s) is not covered by a Composition of Matter Claim of Roche. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Pieris&#146; obligation to pay royalties to Roche shall, with respect to such Product(s) and for a given country, start on the date of First
Commercial Sale of such Product(s) in such country and end on the later of the date that is (a)&nbsp;[***] after the date of the First Commercial Sale of such Product(s) in such country, or (b)&nbsp;the expiration of the last to expire Composition
of Matter Claim of a patent owned or Controlled by Roche (or by Pieris pursuant to Sections 14.5 or 19.3.4) in such country Covering the use, import, offering for sale, or sale of such Product(s). Sections 10.6.3.2, 10.7 and 10.8 shall apply mutatis
mutandis to the royalty rate owed by Pieris to Roche. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="8%">&nbsp;</TD> 
<TD WIDTH="5%" VALIGN="top" ALIGN="left">v.</TD> 
<TD ALIGN="left" VALIGN="top">The obligation of Roche to manufacture and supply the Product(s) to Pieris during a transition period at [***], until such time as Pieris has procured or developed its own source of Product supply, provided that Pieris
can demonstrate it has been diligently seeking an alternative manufacturer and provided further that in any case Roche&#146;s manufacture and supply obligation shall in no event exceed [***] from the effective date of the termination of this
Agreement, except as provided below. Pieris shall use Commercially Reasonable Efforts to establish or take over the manufacturing as soon as possible after the effective date of termination. In case termination occurs before Phase II Studies have
been Initiated, Pieris shall, at the request of Roche, use Commercially Reasonable Efforts to develop their [***] to be used in pivotal studies. In case termination occurs when Phase II Studies have already been Initiated or later, Roche shall
reasonably cooperate in assisting Pieris in the transfer of manufacturing process for such Product to a Third Party manufacturer, provided such Third Party manufacturer is acceptable to Roche; and Roche shall transfer the [***] to such Third Party
manufacturer. Except as provided herein, Roche shall be under no obligation to provide, transfer or allow Pieris to use proprietary [***], or disclose proprietary [***] related to the Product(s). In case termination occurs after Initiation of Phase
III Studies, Roche shall, upon Pieris&#146; request, [***] for the manufacture of Product(s) to the Third Party manufacturer acceptable to Roche. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="8%">&nbsp;</TD> 
<TD WIDTH="5%" VALIGN="top" ALIGN="left">vi.</TD> 
<TD ALIGN="left" VALIGN="top">In case the necessary transfers under subsections (i), (ii)&nbsp;and (v)&nbsp;have not been achieved within the foreseen timelines due to difficulties not under control of the Parties, then Roche shall reasonably
cooperate and assist Pieris for a reasonable additional period not to exceed [***] (such difficulties can consist in, for example, a regulatory approval being delayed). </TD></TR></TABLE> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 45 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c)</TD> 
<TD ALIGN="left" VALIGN="top">For clarity, the licenses under this Section&nbsp;19.3.4.a) and b) shall not include (i)&nbsp;any licenses that Roche has with a Third Party for which such grant would be prohibited or under which a member of the Roche
Group would incur financial obligations to such Third Party, provided, however, that Roche shall (a)&nbsp;sublicense such Third Party licenses to Pieris if allowed in the respective license agreement, subject to Pieris committing to assume full
responsibility for any and all financial obligations owed by Roche to such Third Party for the sublicense, and (b)&nbsp;reasonably support Pieris in getting in contact with such Third Party, for which a sublicense is not permitted, to get access to
such Third Party rights, and (ii)&nbsp;the Excluded Patent Rights. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19.3.5 Direct License </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Irrespective of anything to the contrary in this Agreement, any existing, permitted sublicense granted by Roche under Section&nbsp;2.3 of this Agreement (and
any further sublicenses thereunder) shall, upon the written request of Roche, remain in full force and effect, provided that (i)&nbsp;such Sublicensee is not then in breach of its sublicense agreement (and, in the case of termination by Pieris for
breach by Roche, that such Sublicensee and any further sublicensees did not cause the breach that gave rise to the termination by Pieris); and (ii)&nbsp;and such Sublicensee agrees to be bound to Pieris under the terms and conditions of such
sublicense agreement, provided that the payments due to Pieris by such Sublicensee under such sublicense agreement are no less than the payments that would have been due to Pieris by Roche under this Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19.3.6 Other Activities </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19.3.6.1 Ongoing Activities </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If Pieris does not
provide timely Continuation Election Notice (Section 19.3.4), then Roche (a)&nbsp;shall have the right to cancel all ongoing activities and (b)&nbsp;shall complete all non-cancellable activities at its own expense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If Pieris provides such timely Continuation Election Notice, then from the date of notice of termination until the effective date of termination, Roche shall,
at Pieris&#146; request and expense, continue activities performed by or on behalf of Roche, including preparatory activities, ongoing as of the date of notice of termination. However, subject to Section&nbsp;19.3.4, Roche shall not be obliged to
initiate any new activities not ongoing at the date of notice of termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After the effective date of termination and to the extent that Pieris has
not made a request as described above, Roche shall not have any obligation to perform and/or complete any activities or to make any payments for performing or completing any activities under this Agreement, except as expressly stated herein. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19.3.6.2 Royalty and Payment Obligations </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Termination of this Agreement by a Party, for any reason, shall not release Roche from any obligation to pay royalties or make any payments to Pieris that are
due and payable prior to the effective date of termination. </P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 46 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>19.4 Survival </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.2 (Late Payment), Article 13 (Auditing), Article 14 (Intellectual Property), Article 16 (Indemnification), Article 18 (Obligation Not to
Disclose Confidential Information), Article 19 (Term and Termination), Section&nbsp;21.1 (Governing Law), Section&nbsp;21.2 (Disputes), Section&nbsp;21.12 (Notice) and all definitions used in such Articles and Sections shall survive any expiration
or termination of this Agreement for any reason. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>20. Bankruptcy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All licenses (and to the extent applicable rights) granted under or pursuant to this Agreement by Pieris to Roche are, and shall otherwise be deemed to be, for
purposes of Section&nbsp;365(n) of Title 11, US Code (the &#147;<B>Bankruptcy Code</B>&#148;) licenses of rights to &#147;intellectual property&#148; as defined under Section&nbsp;101(60) of the Bankruptcy Code. Unless Roche elects to terminate this
Agreement, the Parties agree that Roche, as a licensee or sublicensee of such rights under this Agreement, shall retain and may fully exercise all of its rights and elections under the Bankruptcy Code, subject to the continued performance of its
obligations under this Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21. Miscellaneous </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21.1 Governing Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Agreement shall be governed by
and construed in accordance with the laws of Germany, without reference to its conflict of laws principles, and shall not be governed by the United Nations Convention of International Contracts on the Sale of Goods (the Vienna Convention). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21.2 Disputes </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="4%">&nbsp;</TD> 
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD> 
<TD ALIGN="left" VALIGN="top">Unless otherwise set forth in this Agreement, in the event of any dispute in connection with this Agreement, such dispute shall be referred to the respective executive officers of the Parties designated below or their
designees, for good faith negotiations attempting to resolve the dispute. The designated executive officers are as follows: </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">For Pieris: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CEO </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:17%; font-size:10pt; font-family:Times New Roman">For Roche: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Head of Roche Partnering </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%"> 
<TR> 
<TD WIDTH="4%">&nbsp;</TD> 
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD> 
<TD ALIGN="left" VALIGN="top">Should the Parties fail to agree within [***] after such dispute has been referred to the Parties&#146; designated executive officers, then either Party shall be entitled to request resolution of the dispute through
arbitration, which shall be finally settled under the Rules of Arbitration of the International Chamber of Commerce by three (3)&nbsp;arbitrators appointed in accordance with said Rules. The place of arbitration shall be Basel, Switzerland. The
language to be used in the arbitration proceeding shall be English. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21.3 Assignment </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither Party shall have the right to assign the present Agreement or any part thereof to any Third Party other than Affiliates without the prior written
approval of the other Party which shall not unreasonably be withheld, provided however, if a Party is acquired or is to be acquired by a third party by merger, acquisition, or the sale of substantially all of the assets of the division of such Party
to which the subject matter of this Agreement relates, then such Party may effect such an assignment or transfer to such acquiring Third Party without the consent of the other Party. </P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 47 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21.4 Debarment </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each Party represents and warrants that it has never been debarred or otherwise sanctioned by the FDA, or a corresponding regulatory authority. Neither Party
has been debarred under 21 U.S.C. &#167;335a, disqualified under 21 C.F.R. &#167;312.70 or &#167;812.119, sanctioned by a Federal Health Care Program (as defined in 42 U.S.C &#167;1320 a-7b(f)), including without limitation the federal Medicare or a
state Medicaid program, or debarred, suspended, excluded or otherwise declared ineligible from any other similar Federal or state agency or program. In the event either Party receives notice of debarment, suspension, sanction, exclusion,
ineligibility or disqualification under the above-referenced statutes, such Party shall immediately notify the other Party in writing and such other Party shall have the right, but not the obligation, to terminate this Agreement, effective, at such
Party&#146;s option, immediately or at a specified future date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21.5 Independent Contractor </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No employee or representative of either Party shall have any authority to bind or obligate the other Party to this Agreement for any sum or in any manner
whatsoever or to create or impose any contractual or other liability on the other Party without said Party&#146;s prior written approval. For all purposes, and notwithstanding any other provision of this Agreement to the contrary, Pieris&#146; legal
relationship to Roche under this Agreement shall be that of independent contractor. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21.6 Unenforceable Provisions and Severability </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any of the provisions of this Agreement are held to be void or unenforceable, then such void or unenforceable provisions shall be replaced by valid and
enforceable provisions that will achieve as far as possible the economic business intentions of the Parties. However the remainder of this Agreement will remain in full force and effect, provided that the material interests of the Parties are not
affected, i.e. the Parties would presumably have concluded this Agreement without the unenforceable provisions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21.7 Waiver </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The failure by either Party to require strict performance and/or observance of any obligation, term, provision or condition under this Agreement will neither
constitute a waiver thereof nor affect in any way the right of the respective Party to require such performance and/or observance. The waiver by either Party of a breach of any obligation, term, provision or condition hereunder shall not constitute
a waiver of any subsequent breach thereof or of any other obligation, term, provision or condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21.8 Appendices </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All Appendices to this Agreement shall form an integral part to this Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21.9 Entire Understanding </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Agreement contains the
entire understanding between the Parties hereto with respect to the within subject matter and supersedes any and all prior agreements, understandings and arrangements, whether written or oral. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21.10 Amendments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No amendments of the terms and
conditions of this Agreement shall be binding upon either Party hereto unless in writing and signed by both Parties. </P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 48 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21.11 Invoices </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All invoices that are required or permitted hereunder shall be in writing and sent by Pieris to Roche at the following address or other address as Roche may
later provide: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">F. Hoffmann-La Roche Ltd </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Switzerland </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>21.12 Notice </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All notices that are required or permitted
hereunder shall be in writing and sufficient if delivered personally, sent by facsimile (and promptly confirmed by personal delivery, registered or certified mail or overnight courier), sent by nationally recognized overnight courier or sent by
registered or certified mail, postage prepaid, return receipt requested, addressed as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right"> 
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">

 
<TR> 
<TD WIDTH="20%"></TD> 
<TD VALIGN="bottom" WIDTH="2%"></TD> 
<TD WIDTH="78%"></TD></TR>

 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top">if&nbsp;to&nbsp;Pieris,&nbsp;to:</TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pieris Pharmaceuticals GmbH</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lise-Meitner-strasse 30</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">85354 Freising</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Germany</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: CEO</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Facsimile No.: [***]</P></TD></TR> 
<TR STYLE="font-size:1pt"> 
<TD HEIGHT="8"></TD> 
<TD HEIGHT="8" COLSPAN="2"></TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top">and:</TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pieris Pharmaceuticals, Inc.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">255 State Street,
9<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> floor</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, MA 02109</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S.A</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: CEO</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Facsimile No.: [***]</P></TD></TR> 
<TR STYLE="font-size:1pt"> 
<TD HEIGHT="8"></TD> 
<TD HEIGHT="8" COLSPAN="2"></TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top">if&nbsp;to&nbsp;Roche,&nbsp;to:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">F. Hoffmann-La Roche Ltd</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Switzerland</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Legal Department</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Facsimile No.: [***]</P></TD></TR> 
<TR STYLE="font-size:1pt"> 
<TD HEIGHT="8"></TD> 
<TD HEIGHT="8" COLSPAN="2"></TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top">and:</TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hoffmann-La Roche Inc.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S.A.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn. Corporate Secretary</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Facsimile No.: [***]</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or to such other address as the Party to whom notice is to be given may have furnished to the other Party in writing in
accordance herewith. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page Follows] </I></P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 49 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have entered into this Agreement as of the Effective Date. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> 
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">

 
<TR> 
<TD WIDTH="47%"></TD> 
<TD VALIGN="bottom" WIDTH="1%"></TD> 
<TD WIDTH="4%"></TD> 
<TD VALIGN="bottom" WIDTH="1%"></TD> 
<TD WIDTH="47%"></TD></TR>

 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pieris Pharmaceuticals GmbH</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Stephen S. Yoder</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name:
Stephen S. Yoder</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title: President &amp; CEO</P></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"></TD></TR> 
<TR STYLE="font-size:1pt"> 
<TD HEIGHT="16"></TD> 
<TD HEIGHT="16" COLSPAN="2"></TD> 
<TD HEIGHT="16" COLSPAN="2"></TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pieris Pharmaceuticals, Inc.</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Stephen S. Yoder</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name:
Stephen S. Yoder</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title: President &amp; CEO</P></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"></TD></TR> 
<TR STYLE="font-size:1pt"> 
<TD HEIGHT="16"></TD> 
<TD HEIGHT="16" COLSPAN="2"></TD> 
<TD HEIGHT="16" COLSPAN="2"></TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"><B>F. Hoffmann-La Roche Ltd</B></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"></TD></TR> 
<TR STYLE="font-size:1pt"> 
<TD HEIGHT="16"></TD> 
<TD HEIGHT="16" COLSPAN="2"></TD> 
<TD HEIGHT="16" COLSPAN="2"></TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Vikas Kabra</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name: Vikas Kabra</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title: Head of Transaction Excellence</P></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Dr. Christof Burri</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name: Dr. Christof Burri</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title: Legal Counsel</P></TD></TR> 
<TR STYLE="font-size:1pt"> 
<TD HEIGHT="16"></TD> 
<TD HEIGHT="16" COLSPAN="2"></TD> 
<TD HEIGHT="16" COLSPAN="2"></TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Hoffmann-La Roche Inc.</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John P. Parise</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name: John P.
Parise</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title: Authorized Signatory</P></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;</TD> 
<TD VALIGN="top"></TD></TR>
</TABLE> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 50 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Appendix 1.60 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pieris IP </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the
exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and
Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of
the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Appendix 1.66 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Research Plan </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>[***] </B></P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 52 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 53 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 54 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 55 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 56 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 57 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 58 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 59 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 60 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 61 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 62 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Appendix 1.68 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Excluded Patent Rights </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 63 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 64 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Appendix 1.74 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>[***] </B></P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 65 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 66 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Appendix 18.3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Press Release </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g111873image001.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>PRESS RELEASE </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pieris Pharmaceuticals Announces </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>First Cancer Immunotherapy Collaboration </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Agreement with Roche Leverages Proprietary Anticalin<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Technology Platform </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Boston, MA, December&nbsp;8, 2015 </B>&#150; Pieris Pharmaceuticals, Inc.&nbsp;(NASDAQ: PIRS), a biotechnology company advancing novel bio therapeutics
through its proprietary&nbsp;Anticalin<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;technology platform, today announced a research collaboration and license agreement with Roche in cancer immunotherapy (CIT). Under the terms of
the agreement, Pieris will discover, characterize and optimize Anticalin<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>-based drug candidates against an undisclosed target. Roche and Pieris will evaluate different drug formats against
this target and advance them through preclinical development, with Roche being responsible for IND-enabling activities, clinical development and worldwide marketing of any resulting products. Pieris will receive an upfront payment of CHF
6.5&nbsp;million (~$6.4 million USD) and committed research funding, and may receive development and regulatory-based milestone payments, sales-based milestone payments as well as mid single-digit to low double-digit royalties on any future product
sales. If all milestones and other conditions are met, the total payments to Pieris could surpass CHF 415&nbsp;million (~$409.3 million USD), excluding royalties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Our partnership with Roche is a significant step forward for Pieris,&#148; commented Stephen Yoder, President and CEO of Pieris. &#147;The decision by
the leader in the development and commercialization of cancer biologics to collaborate with Pieris underscores the unique potential of Anticalin-based proteins as a differentiated class of immuno-oncology drugs. As we initiate this collaboration, we
will continue to vigorously advance our fully proprietary programs, including our lead CD137-HER2 bispecific.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With its immuno-oncology PRS-300
Series, which remains proprietary to the Company, Pieris is developing bispecific Anticalin-based protein therapeutics against a variety of tumor and immunomodulatory targets. These compounds, including its lead program PRS-343 (CD137/HER2
bispecific), aim to activate the immune system in the tumor microenvironment, with the goal of increasing efficacy as well as improving safety compared to existing approaches. This collaboration represents Pieris&#146; first partnered
immuno-oncology program and leverages Pieris&#146; capability to address a target in multiple ways through Anticalin-based drug candidates in different formats. </P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 67 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Pieris Pharmaceuticals: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pieris Pharmaceuticals is a clinical stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways in a
unique and transformative way.&nbsp;Our pipeline includes immuno-oncology multi-specifics tailored for the tumour micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Proprietary
to Pieris, Anticalins are a novel class of protein therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies.&nbsp;Anticalin<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, Anticalins<SUP 
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> are registered trademarks of Pieris. For more information visit&nbsp;www.pieris.com. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About
Anticalins: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Anticalins are derived from lipocalins, small human proteins that naturally bind, store and transport a wide spectrum of molecules.
Anticalins feature the typical four-loop variable region and a rigidly conserved beta-barrel backbone of lipocalins, which, together, form a shapeable cup-like binding pocket. Proprietary to Pieris, Anticalins are a novel class of protein
therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Anticalin<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, Anticalins<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> are registered
trademarks of Pieris. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements as that term is defined in Section&nbsp;27A of the Securities Act of 1933 and Section&nbsp;21E of the
Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to novel technologies and methods; our business,
research and product development plans; our liquidity and ability to fund our future operations; our ability to achieve certain milestones and receive future milestone or royalty payments; or market information. Actual results could differ from
those projected in any forward-looking statements due to numerous factors. Such factors include, among others, our ability to raise the additional funding we will need to continue to pursue our business, research and product development plans; the
inherent uncertainties associated with developing new products or technologies and operating as a development stage company; our ability to develop, complete clinical trials for, obtain approvals for and commercialize any of our product candidates;
competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this press release, and we assume no obligation to update the forward-looking statements, or to update the reasons why
actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the
reports and other documents we file with the SEC available at www.sec.gov, including without limitation the Company&#146;s Annual Report on Form 10-K for the fiscal year ended December&nbsp;31, 2014 and the Company&#146;s Quarterly Reports on Form
10-Q. </P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 68 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
 
<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
  

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CONFIDENTIAL TREATMENT REQUESTED </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

 
<TR> 
<TD WIDTH="51%"></TD> 
<TD VALIGN="bottom" WIDTH="2%"></TD> 
<TD WIDTH="47%"></TD></TR>

 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"><B>Company Contact:</B></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="top"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investor Relations Contact:</B></TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top">Pieris Pharmaceuticals, Inc.</TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="top">The Trout Group</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top">Darlene Deptula-Hicks</TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Thomas Hoffmann</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top">SVP and Chief Financial Officer</TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;+1-646-378-2931</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top">+1-603-553-5803</TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="top"><U>thoffmann@troutgroup.com</U></TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"><U>deptula@pieris.com</U></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="top"></TD></TR> 
<TR STYLE="font-size:1pt"> 
<TD HEIGHT="8"></TD> 
<TD HEIGHT="8" COLSPAN="2"></TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;or</TD></TR> 
<TR STYLE="font-size:1pt"> 
<TD HEIGHT="8"></TD> 
<TD HEIGHT="8" COLSPAN="2"></TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"><B>Media Inquiries:</B></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Del Mar Consulting Group, Inc.</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top">Gretchen Schweitzer</TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Robert Prag, President</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top">+49 172 861 8540</TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;+1-858-794-5000</TD></TR> 
<TR STYLE="font-family:Times New Roman; font-size:10pt"> 
<TD VALIGN="top"><U>gschweitzer@macbiocom.com</U></TD> 
<TD VALIGN="bottom">&nbsp;&nbsp;</TD> 
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>bprag@delmarconsulting.com</U></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">##END## </P> 
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 69 - </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Portions of the exhibit, indicated by the mark &#147;[***],&#148; were omitted and have been filed separately </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with the Securities and Exchange Commission pursuant to the Registrant&#146;s application requesting </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </I></B></P> 
 
</BODY></HTML>
</TEXT>
</DOCUMENT>
